<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000091.pub2" GROUP_ID="STROKE" ID="601599072910111474" MERGED_FROM="" MODIFIED="2013-10-31 15:18:29 +0000" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2013-10-31 15:15:06 +0000" MODIFIED_BY="Hazel Fraser">
<TITLE>Fibrinogen depleting agents for acute ischaemic stroke</TITLE>
<CONTACT>
<PERSON ID="16502" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Ming</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Liu</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Neurology</POSITION>
<EMAIL_1>wyplmh@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8542 3551</PHONE_1>
<PHONE_2/>
<FAX_1>+86 28 8542 3551</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-10-31 15:14:11 +0000" MODIFIED_BY="Hazel Fraser">
<PERSON ID="593849A382E26AA201AFF012A28D18B2" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Zilong</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hao</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>zhilong1983@126.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8542 3551</PHONE_1>
<PHONE_2/>
<FAX_1>+86 28 8542 3551</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16502" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Ming</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Liu</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Neurology</POSITION>
<EMAIL_1>wyplmh@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8542 3551</PHONE_1>
<PHONE_2/>
<FAX_1>+86 28 8542 3551</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16452" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carl</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Counsell</LAST_NAME>
<SUFFIX/>
<POSITION>Reader in Neurology</POSITION>
<EMAIL_1>carl.counsell@abdn.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Applied Health Sciences</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>Polwarth Building</ADDRESS_1>
<ADDRESS_2>Foresterhill</ADDRESS_2>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2ZD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1224 437119</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1224 551188</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8267" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Joanna</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Wardlaw</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Neuroradiology and Honourary Consultant Neuroradiologist</POSITION>
<EMAIL_1>joanna.wardlaw@ed.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Clinical Neurosciences</DEPARTMENT>
<ORGANISATION>University of Edinburgh</ORGANISATION>
<ADDRESS_1>Western General Hospital</ADDRESS_1>
<ADDRESS_2>Crewe Rd</ADDRESS_2>
<CITY>Edinburgh</CITY>
<ZIP>EH4 2XU</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 131 537 3110</PHONE_1>
<PHONE_2/>
<FAX_1>+44 131 332 5150</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2D65BCD182E26AA2002F1D7AC516CAA1" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Sen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lin</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>wumu8413@163.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16566" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Xiaoling</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Zhao</LAST_NAME>
<SUFFIX/>
<POSITION>Doctor</POSITION>
<EMAIL_1>zfreda@yeah.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-10-30 14:21:18 +0000" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="5" MONTH="12" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="10" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="7" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2013-10-31 15:15:06 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-10-31 15:15:06 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="31" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Missing headings added to forest plots.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-10-31 15:14:35 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-10-31 15:14:35 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="5" MONTH="12" YEAR="2011"/>
<DESCRIPTION>
<P>New first author</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-10-31 15:14:33 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="5" MONTH="12" YEAR="2011"/>
<DESCRIPTION>
<P>Three trials (2775 patients) have been added to this review. However, the conclusions have not changed. The evidence is still not strong enough to recommend the routine use of fibrinogen depleting agents for the treatment of acute ischaemic stroke</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-12-13 14:22:42 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-12-13 14:22:46 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="4" YEAR="2003"/>
<DESCRIPTION>
<P>Changes from previous version of this review are as follows: data from two big trials (2744 extra patients) have been added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-12-13 15:02:12 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>West China Hospital, Sichuan University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Chinese Cochrane Centre, Chinese Centre of Evidence-based Medicine</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2011-12-13 15:02:12 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Chest, Heart and Stroke Scotland</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-12-13 15:02:12 +0000" MODIFIED_BY="Hazel Fraser">
<NAME>World Health Organization</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Wellcome Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Edinburgh</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>China Medical Board of New York (Grant number: 98-680)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-12-05 13:30:05 +0000" MODIFIED_BY="[Empty name]">
<NAME>University of Aberdeen</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Employing institution for Dr Counsell</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-01-11 15:04:56 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-12-13 15:29:04 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-12-13 15:06:30 +0000" MODIFIED_BY="Hazel Fraser">Fibrinogen depleting agents may help to remove blood clots in acute ischaemic stroke</TITLE>
<SUMMARY_BODY MODIFIED="2011-12-13 15:29:04 +0000" MODIFIED_BY="[Empty name]">
<P>Fibrinogen depleting agents are promising but unproven for acute ischaemic stroke. Most strokes are due to a blood clot blocking an artery in the brain. Fibrinogen depleting agents may help remove the blood clot to restore the blood supply to the brain and so improve the chance of making a recovery from the stroke. Fibrinogen depleting agents also reduce blood thickness (or viscosity), which also helps to improve blood flow to the brain. However, these agents can also cause serious bleeding in the brain. Evidence from this updated review, which includes eight trials involving 5701 participants, indicates that there is currently not sufficient evidence to support the routine use of fibrinogen depleting agents for the treatment of acute ischaemic stroke. Further trials are needed to determine reliably whether there is worthwhile benefit, and if so, which categories of patients are most likely to benefit.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-01-11 15:04:56 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-01-11 15:04:56 +0000" MODIFIED_BY="Hazel Fraser">
<P>Fibrinogen depleting agents reduce fibrinogen in blood plasma, reduce blood viscosity and hence increase blood flow. This may help remove the blood clot blocking the artery and re-establish blood flow to the affected area of the brain after an ischaemic stroke. The risk of haemorrhage may be less than with thrombolytic agents. This is an update of a Cochrane review first published in 1997 and last updated in 2003.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-08-20 15:02:31 +0100" MODIFIED_BY="Hazel Fraser">
<P>To assess the effect of fibrinogen depleting agents in patients with acute ischaemic stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-01-11 14:59:00 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Stroke Group Trials Register (July 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2011, Issue 7), the Chinese Stroke Trials Register (September 2011), MEDLINE (1950 to July 2011), EMBASE (1980 to July 2011) and Web of Science Conference Proceedings (1990 to July 2011). In addition, we searched six Chinese databases, four ongoing trials registers (July 2011) and relevant reference lists. For previous versions of the review, we handsearched journals and contacted researchers in China and Japan and relevant drug companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-12-01 08:52:02 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trials of fibrinogen depleting agents started within 14 days of stroke onset, compared with control in patients with definite or possible ischaemic stroke.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-12-13 15:26:37 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently selected trials, assessed trial quality and extracted the data. We resolved disagreement by discussion.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-01-11 14:59:05 +0000" MODIFIED_BY="[Empty name]">
<P>We included eight trials involving 5701 patients. Six trials tested ancrod and two trials tested defibrase (patients were treated for less than three hours to less than 48 hours). Allocation concealment was adequate in seven trials. Fibrinogen depleting agents marginally reduced the proportion of patients who were dead or disabled at the end of follow-up (risk ratio (RR) 0.95, 95% confidence Interval (CI) 0.90 to 0.99, 2P = 0.02). There was no statistically significant difference in death from all causes during the scheduled treatment or follow-up period. There were fewer stroke recurrences in the treatment group than in the control group (RR 0.67, 95% CI 0.49 to 0.92, 2P = 0.01). However, symptomatic intracranial haemorrhage was about twice as common in the treatment group compared with the control group (RR 2.42, 95% CI 1.65 to 3.56, 2P &lt; 0.00001).<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-10-04 07:50:09 +0100" MODIFIED_BY="[Empty name]">
<P>The current evidence is promising but not yet sufficiently robust to support the routine use of fibrinogen depleting agents for the treatment of acute ischaemic stroke. Further trials are needed to determine whether there is worthwhile benefit, and if so, which categories of patients are most likely to benefit.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-01-11 14:59:09 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-12-14 12:17:14 +0000" MODIFIED_BY="Hazel Fraser">
<P>Stroke is a leading cause of death and disability in the world. Despite improvements in prevention (<LINK REF="REF-Collins-1990" TYPE="REFERENCE">Collins 1990</LINK>; <LINK REF="REF-ATT-2002" TYPE="REFERENCE">ATT 2002</LINK>; <LINK REF="REF-Cina-2002" TYPE="REFERENCE">Cina 2002</LINK>; <LINK REF="REF-SPARCL-2006" TYPE="REFERENCE">SPARCL 2006</LINK>), little progress has been made in treating stroke with specific interventions once it has occurred. At present, stroke unit care, intravenous tissue plasminogen activator within three to four-and-a-half hours or aspirin within 48 hours of stroke onset, and decompressive surgery for supratentorial malignant hemispheric cerebral infarction are proven beneficial (<LINK REF="REF-Donnan-2008" TYPE="REFERENCE">Donnan 2008</LINK>; <LINK REF="REF-Hacke-2008" TYPE="REFERENCE">Hacke 2008</LINK>). But the short therapeutic time window (less than three to four-and-a-half hours) (<LINK REF="REF-Donnan-2008" TYPE="REFERENCE">Donnan 2008</LINK>; <LINK REF="REF-Hacke-2008" TYPE="REFERENCE">Hacke 2008</LINK>) and increased intracranial haemorrhage (<LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>) limits the use of thrombolysis. New effective therapeutic strategies should be investigated further.</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-12-13 14:23:41 +0000" MODIFIED_BY="Hazel Fraser">
<P>Several extracts from the venom of pit vipers have been shown to cleave circulating fibrinogen (e.g. ancrod, batroxobin) rather than fibrin. These agents, referred to as fibrinogen depleting agents, may be beneficial in patients with acute ischaemic stroke and indeed they are used to treat such patients in some countries (<LINK REF="REF-Chen-1997" TYPE="REFERENCE">Chen 1997</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2011-12-13 14:23:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>Reduction of plasma fibrinogen leads to reduced blood viscosity and hence increased blood flow and may prevent clot formation or extension (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>). These drugs also appear to promote the release of endogenous tissue plasminogen activator and therefore have some indirect thrombolytic activity (<LINK REF="REF-Pollack-1990" TYPE="REFERENCE">Pollack 1990</LINK>). Moreover, the risk of haemorrhage may be less than with conventional thrombolytic agents.</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-01-11 14:59:09 +0000" MODIFIED_BY="Hazel Fraser">
<P>Ancrod has been used in a variety of conditions for a number of years and the risk of major haemorrhage appears to be small (<LINK REF="REF-Latallo-1983" TYPE="REFERENCE">Latallo 1983</LINK>; <LINK REF="REF-Pollack-1990" TYPE="REFERENCE">Pollack 1990</LINK>). However, before routine use of these agents in stroke patients can be recommended, their efficacy and safety (especially the risk of major intracranial and extracranial haemorrhage) needs to be confirmed in randomised controlled trials (RCTs). We therefore undertook this to review systematically all such RCTs of fibrinogen depleting agents in patients with acute ischaemic stroke. In a previous version of this Cochrane review (<LINK REF="REF-Liu-2003" TYPE="REFERENCE">Liu 2003</LINK>), five trials including 2926 patients were analysed. Ancrod appeared to be promising, but the evidence base was too small to draw any reliable conclusions. Since then a further three trials of fibrinogen depleting agents for acute ischaemic stroke have been published (<LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>). Therefore, the aim of this version is to update the current randomised evidence to see if there is enough reliable evidence to recommend wider use of fibrinogen depleting agents for acute ischaemic stroke.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-12-13 14:24:40 +0000" MODIFIED_BY="Hazel Fraser">
<P>We wished to test the following hypotheses.</P>
<OL>
<LI>Fibrinogen depleting agents reduce the long term risk of death and disability, without an increased risk of early death.</LI>
<LI>Fibrinogen depleting agents reduce the early recurrence of ischaemic stroke.</LI>
<LI>The risk of haemorrhage does not outweigh the benefits.</LI>
<LI>Early treatment is more beneficial than treatment started later (less than six hours only versus the rest, less than three hours only versus the rest).</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2012-01-11 14:59:18 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-01-10 11:33:54 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-12-13 14:24:52 +0000" MODIFIED_BY="[Empty name]">
<P>We only included unconfounded truly randomised controlled trials comparing fibrinogen depleting agents with placebo or open control in patients with acute ischaemic stroke.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-08-20 15:22:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>Trials which included patients of any age or sex within 14 days of onset of a presumed ischaemic stroke were eligible. Ischaemic stroke was defined as either definite (i.e. haemorrhage had been excluded by computed tomography (CT) or magnetic resonance (MR) scanning) or possible (i.e. CT/MR scanning had not been performed).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-01-10 11:33:54 +0000" MODIFIED_BY="[Empty name]">
<P>We included all types of fibrinogen depleting agents, such as ancrod (extract from <I>Agkistrodon rhodostoma</I> venom), defibrase (extract from Ahylysantinfarctase or BaiMei Pallas Pit Viper), batroxobin (extract from <I>Bothrops moojeni</I> venom) and extracts from other types of snake venom (<I>Agkistrodon Acutus</I> and <I>Agkistrodon halys</I> venom). We excluded confounded trials in which the treatment or control group received another active therapy (e.g. fibrinogen depleting agent plus other agent versus control or fibrinogen depleting agents versus another agent).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-12-13 15:35:19 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-12-13 15:35:19 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death or dependency at the end of the scheduled follow-up period. We classified patients as being disabled if they were dependent on others for activities of daily living.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-12-13 14:25:55 +0000" MODIFIED_BY="Hazel Fraser">
<OL>
<LI>Death from any cause during the scheduled treatment period and the scheduled follow-up period.</LI>
<LI>Symptomatic intracranial (intracerebral, subdural, subarachnoid, extradural) haemorrhage i.e. the haemorrhage was detected by a CT scan or MR scan after clinical deterioration, or at autopsy.</LI>
<LI>Any intracranial haemorrhage (symptomatic or asymptomatic) during the scheduled treatment period (i.e. intracranial haemorrhage was sought systematically by CT/MR scan in all patients who survived to the end of the scheduled treatment period and at autopsy in those who died).</LI>
<LI>Recurrent stroke due to confirmed ischaemia (i.e. haemorrhage excluded by CT/MR scan or autopsy).</LI>
<LI>Recurrent stroke of unknown type (i.e. no CT/MR scan or autopsy). For intracranial haemorrhage or recurrent stroke, we attempted to classify each as fatal, major non-fatal (i.e. alive but disabled/dependent at the end of scheduled follow-up period), and minor non-fatal (i.e. alive and independent at the end of scheduled follow-up period).</LI>
<LI>Major extracranial haemorrhage (i.e. fatal or requiring surgery or requiring transfusion).</LI>
<LI>Deep venous thrombosis (DVT) during the scheduled treatment period if this was systematically sought (i.e. if DVT was looked for in all survivors using an imaging technique).</LI>
<LI>Pulmonary embolism during the scheduled treatment period.</LI>
<LI>Fatal or non-fatal myocardial infarction.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-12-13 15:39:57 +0000" MODIFIED_BY="Carl Counsell">
<P>See the 'Specialized register' section in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/stroke/frame.html">Cochrane Stroke Group</A> module.</P>
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Managing Editor in July 2011. In addition, in collaboration with the Cochrane Stroke Group Trials Search Co-ordinator, we searched the following bibliographic databases:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library 2011</I>, Issue 7) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>MEDLINE (1950 to July 2011) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>EMBASE (1980 to July 2011) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>);</LI>
<LI>Web of Science Conference Proceedings (1990 to July 2011) using the terms "ancrod" or "batroxobin" or "defibrase".</LI>
</UL>
<P>In an effort to identify further published, unpublished and ongoing trials:</P>
<OL>
<LI>we searched the following Chinese databases using the terms ("defibrase" or "snake venom " or "batroxobin") and ("stroke" or "cerebrovascular disease"):</LI>
<OL>
<LI>The Chinese Stroke Trials Register (September 2011);</LI>
<LI>China Biological Medicine Databases (CBM-disc) (1981 to July 2011);</LI>
<LI>China National Knowledge Infrastructure (CNKI) (1979 to July 2011);</LI>
<LI>Chinese MD and DD Dissertations in CNKI (1979 to July 2011);</LI>
<LI>Chinese Academic Conference Papers Database (CACP) (1985 to July 2011);</LI>
<LI>Wanfang Data (<A HREF="http://www.wanfangdata.com/">http://www.wanfangdata.com/</A>) (1983 to July 2011);</LI>
<LI>Chinese scientific periodical database of VIP INFORMATION (VIP) (1989 to July 2011);</LI>
</OL>
<LI>we searched the following ongoing trials registers using the terms "ancrod" or "batroxobin" or "defibrase":</LI>
<OL>
<LI>ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">http://www.clinicaltrials.gov/</A>) (July 2011);</LI>
<LI>Current Controlled Trials (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>) (July 2011);</LI>
<LI>National Center for Complementary and Alternative Medicine (<A HREF="http://www.nccam.nih.gov/clinicaltrials/">http://www.nccam.nih.gov/clinicaltrials/</A>) (July 2011);</LI>
<LI>Stroke Trials Directory (<A HREF="http://www.strokecenter.org/trials/">www.strokecenter.org/trials/</A>) (July 2011);</LI>
</OL>
<LI>we searched reference lists of all relevant papers;</LI>
<LI>for previous versions of this review we searched the proceedings of the 4th Chinese Stroke Conference (1995), contacted colleagues in Japan and China and contacted representatives of TOBISHI (manufacturer of batroxobin) and Knoll Pharmaceuticals (ancrod). We also handsearched the following journals:</LI>
<OL>
<LI>
<I>Chinese Journal of Neurology and Psychiatry</I> (renamed <I>Chinese Journal of Neurology,</I> 1965 to 1996);</LI>
<LI>
<I>Chinese Journal of Nervous and Mental Diseases</I> (1980 to 1996);</LI>
<LI>
<I>Chinese Journal of Neurosurgery </I>(1985 to 1995);</LI>
<LI>
<I>Chinese Journal of Internal Medicine</I> (1989 to 1995);</LI>
<LI>
<I>Chinese Medical Journal (Beijing) </I>(1987 to 1995);</LI>
<LI>
<I>Journal of Stroke and Neurological Diseases</I> (1984 to 1996);</LI>
<LI>
<I>Journal of Clinical Neurology</I> (1992 to 1996);</LI>
<LI>
<I>Journal of Brain and Neurological Diseases</I> (1995 to 1996).</LI>
</OL>
</OL>
<P>We did not update these searches for this version of the review.</P>
<P>We searched for trials in all languages and arranged translation of relevant reports published in languages other than English and Chinese.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-01-11 14:59:18 +0000" MODIFIED_BY="[Empty name]">
<P>Pairs of review authors (ML and CC, ML and JW, ML and ZH) independently selected the trials to be included in the review. We resolved disagreements by discussion. At least two review authors assessed the methodological quality of each trial by recording details of the randomisation method, blinding, whether an intention-to-treat (ITT) analysis was possible from the published data and the number of patients who were lost to follow-up. They independently extracted the data which were then cross checked. We tried to extract the data on the number of patients with each outcome event, by allocated treatment group, irrespective of compliance, and whether or not the patient was subsequently deemed ineligible or otherwise excluded from treatment or follow-up, in order to allow an ITT analysis. Some of the above data (particularly on outcomes) were not available in the publications, and so we requested further information from Knoll Pharmaceuticals and from the principal trialists of the trials (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>). If data were missing, we performed an available case analysis. The proportion of participants in each group who did not provide data was shown.</P>
<P>We calculated risk ratio (RR) and risk differences (RD) using the Cochrane Review Manager software, RevMan 5.1 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). We examined heterogeneity between trial results using the I<SUP>2</SUP> statistic test.</P>
<P>The main analyses were based on all trials. However, we also planned priori sensitivity analyses based on:</P>
<OL>
<LI>trials with well concealed treatment allocation (i.e. allocation was given by telephoning a central office, by first entering the data into a computer, by the pharmacy, by using identical numbered containers, or by sequentially numbered, sealed, opaque envelopes) versus less well concealed allocation;</LI>
<LI>trials with blinded outcome assessment versus unblinded assessment;</LI>
<LI>trials where all patients had intracranial haemorrhage excluded by CT scan before randomisation versus those without initial CT scanning.</LI>
</OL>
<P>We planned a priori subgroup analyses based on:</P>
<OL>
<LI>the different types of defibrinogenating agents;</LI>
<LI>the different times of starting treatment (less than six hours only versus the rest, less than three hours only versus the rest);</LI>
<LI>individual patient data for patients who entered the trial within three hours, six hours, 12 hours, 24 hours or more than 24 hours after stroke onset;</LI>
<LI>individual patient data for those patients in which the fibrinogen level was lowered to less than 130 mg/dL by treatment versus those where it remained more than 130 mg/dL.</LI>
</OL>
<P>We carried out subgroup analyses (1) and (2) above; we did not perform the other analyses due to the lack of relevant data.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2011-12-13 15:47:52 +0000" MODIFIED_BY="Hazel Fraser">
<P>After reading titles and abstracts, we retained 49 studies for further assessment. Eight trials including a total of 5701 patients were included in this review (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>): we identified three new trials for inclusion in this update (<LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>). Of note, one trial (<LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>) was stopped early for futility reasons. <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK> started as two parallel randomised, double-blind trials, each aiming to recruit 650 participants. The data from the interim analysis (500 participants from two planned trials) were used for the basis of this review.</P>
<P>We excluded 41 studies (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Two studies await classification because we need more details to evaluate them (<LINK REF="STD-Li-1999" TYPE="STUDY">Li 1999</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-01-11 14:59:35 +0000" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of participants in included studies</HEADING>
<P>One trial has only been reported in summary (<LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>) and so few details on patient characteristics were available for this trial. Most patients were relatively young (the mean age ranged from 62 years to 73 years) and there were similar numbers of men and women in the included trials. All patients had a CT scan before treatment to exclude intracranial haemorrhage (<LINK REF="REF-Sherman-1996" TYPE="REFERENCE">Sherman 1996</LINK> - personal communication for <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>). Patients at risk of bleeding (e.g. those with hepatic or renal failure and those on anticoagulant or antiplatelet therapy) were excluded from each trial. Seven trials also excluded patients with severe hypertension, comatose patients, renal or hepatic failure (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>; <LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>), whilst two trials also excluded atrial fibrillation (<LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>), two trials excluded recent stroke (<LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>) and two trials excluded patients with recent ischaemic heart disease (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>). The time from stroke onset to treatment varied from three hours (<LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>) to 48 hours (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions in included studies</HEADING>
<P>Six trials used ancrod, five of which administered it intravenously (<LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>; <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>) and one subcutaneously (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>). Two trials used defibrase (<LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>). Five trials testing ancrod used an initial bolus of between 0.5 to 1.0 unit per kg which was designed to produce a rapid reduction in plasma fibrinogen, followed by variable dosage regimens in order to maintain a plasma fibrinogen concentration of between 70 to 130 mg/dL or 1.18 to 2.03 micromol/l. One recent study (<LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>) used a brief dosing regimen (participants were infused with ancrod 0.167 IU/kg per hour over two or three hours). In one trial the desired fibrinogen level was achieved in only half of the patients within six hours (<LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>), and in another trial the fibrinogen level was achieved in more than 90% of patients within six hours (<LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>). One trial used defibrase 10 IU intravenously on day one, and 5 IU on day three and day five (<LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>). Another trial conducted in China used defibrase 15 IU intravenously on the first day, subsequently 5 IU were infused on the third, fifth, seventh and ninth days respectively (<LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>). Treatment was given for five days in three trials (<LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>), seven days in two trials (<LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>; <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>), nine days in one trial (<LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>) and 14 days in one (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome measures of included studies</HEADING>
<P>Two of the trials concentrated on biochemical and haematological outcomes and few clinical outcomes were reported (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>). Six trials reported activities of daily living in survivors: a good outcome was defined as a Barthel Index score greater than or equal to 90 (out of a maximum of 95 not 100) or the same as the prestroke score in five trials (<LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>; <LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>) and responders combining modified Rankin Scale (mRS) with pretreatment National Institute of Health Stroke Scale (NIHSS) was used in a recent study (<LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>). Responders were defined as follows: (1) participants with a prestroke mRS of 0 to 1 and pretreatment NIHSS score of 5 to 15 who achieved a 90-day mRS of 0 to 1; (2) participants with a prestroke mRS of 0 to 1 and pretreatment NIHSS scores of 16 who achieved a 90-day mRS of 0 to 2; and (3) participants with a prestroke mRS score of 2 or more and any pretreatment NIHSS score which, at 90 days, returned to their prestroke mRS or better.The duration of follow-up was generally adequate: three months in four trials (<LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>) and one year in the other four trials.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="Hazel Fraser">
<P>We excluded 41 trials because of non-random allocation (<LINK REF="STD-CRG-1982" TYPE="STUDY">CRG 1982</LINK>; <LINK REF="STD-Zhang-1996" TYPE="STUDY">Zhang 1996</LINK>); confounding with low molecular weight dextran (<LINK REF="STD-Hao-1984" TYPE="STUDY">Hao 1984</LINK>; <LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Yang-2000" TYPE="STUDY">Yang 2000</LINK>), with a Chinese medicine (<LINK REF="STD-Qiang-1995" TYPE="STUDY">Qiang 1995</LINK>; <LINK REF="STD-Wang-1999" TYPE="STUDY">Wang 1999</LINK>; <LINK REF="STD-Zhang-2002" TYPE="STUDY">Zhang 2002</LINK>), with batroxobin (<LINK REF="STD-Huang-1996" TYPE="STUDY">Huang 1996</LINK>), with ahylsantinfarctase (<LINK REF="STD-Wang-1999a" TYPE="STUDY">Wang 1999a</LINK>), with Ozagrel (<LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>) or with xanthinol nicotinate (<LINK REF="STD-Zhang-2001" TYPE="STUDY">Zhang 2001</LINK>) or conventional treatment (<LINK REF="STD-Kuang-1996" TYPE="STUDY">Kuang 1996</LINK>), or comparison of intravenous administration of batroxobin with intra-carotid artery injection (<LINK REF="STD-Zhang-1998" TYPE="STUDY">Zhang 1998</LINK>); or the outcomes measures were only impairment scales without any of our prespecified outcome measures (<LINK REF="STD-Gao-1996" TYPE="STUDY">Gao 1996</LINK>; <LINK REF="STD-Wu-1997" TYPE="STUDY">Wu 1997</LINK>; <LINK REF="STD-He-1998" TYPE="STUDY">He 1998</LINK>; <LINK REF="STD-Lian-1998" TYPE="STUDY">Lian 1998</LINK>; <LINK REF="STD-Zhao-1999" TYPE="STUDY">Zhao 1999</LINK>; <LINK REF="STD-Cai-2000" TYPE="STUDY">Cai 2000</LINK>; <LINK REF="STD-Chen-2000" TYPE="STUDY">Chen 2000</LINK>; <LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK>; <LINK REF="STD-Yu-2000" TYPE="STUDY">Yu 2000</LINK>; <LINK REF="STD-Fan-2001" TYPE="STUDY">Fan 2001</LINK>; <LINK REF="STD-Du-2003" TYPE="STUDY">Du 2003</LINK>; <LINK REF="STD-Gusev-2006" TYPE="STUDY">Gusev 2006</LINK>); or outcomes measures were laboratory data (<LINK REF="STD-Xu-2000" TYPE="STUDY">Xu 2000</LINK>; <LINK REF="STD-Guo-2008" TYPE="STUDY">Guo 2008</LINK>) or<B> </B>single-centre results from the larger overall trials<B> </B>included in this review (<LINK REF="STD-Cui-2000" TYPE="STUDY">Cui 2000</LINK>; <LINK REF="STD-Fan-2000" TYPE="STUDY">Fan 2000</LINK>; <LINK REF="STD-Li-2000" TYPE="STUDY">Li 2000</LINK>; <LINK REF="STD-Mei-2000" TYPE="STUDY">Mei 2000</LINK>; <LINK REF="STD-Sun-2000" TYPE="STUDY">Sun 2000</LINK>; <LINK REF="STD-Yan-2001" TYPE="STUDY">Yan 2001</LINK>; <LINK REF="STD-Sun-2002" TYPE="STUDY">Sun 2002</LINK>; <LINK REF="STD-Lu-2003" TYPE="STUDY">Lu 2003</LINK>; <LINK REF="STD-Xie-2003" TYPE="STUDY">Xie 2003</LINK>; <LINK REF="STD-Yu-2003" TYPE="STUDY">Yu 2003</LINK>; <LINK REF="STD-Wang-2004" TYPE="STUDY">Wang 2004</LINK>; <LINK REF="STD-Wei-2004" TYPE="STUDY">Wei 2004</LINK>; <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK>). See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-01-11 15:00:10 +0000" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2012-01-11 14:59:50 +0000" MODIFIED_BY="Hazel Fraser">
<P>Seven trials adequately concealed the randomisation sequence from the doctors entering the patients by using sealed, opaque and sequentially numbered envelopes (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>, personal communication) or sequentially numbered identical containers (<LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK> personal communication; <LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>).The concealment of one trial (<LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>) was unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-12-13 15:58:51 +0000" MODIFIED_BY="Hazel Fraser">
<P>Seven trials were double-blind, placebo-controlled trials (<LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>; <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>; <LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>, <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>), but the success of blinding was not recorded. The eighth trial did not use a placebo but the outcome assessor was blind to treatment allocation (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-01-11 15:00:10 +0000" MODIFIED_BY="Hazel Fraser">
<P>Five trials performed an ITT analysis (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="REF-Sherman-1996" TYPE="REFERENCE">Sherman 1996</LINK> (personal communication); <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>). The other three trials did not specifically state that an ITT analysis had been performed. One hundred and forty-seven and 172 exclusions after randomisation occurred in <LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK> and <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>, respectively. No exclusions after randomisation or losses to follow-up were reported in two trials (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>) for the overall outcome. In one trial, losses to follow-up were 88 (7.7%) in the treatment group and 58 (5.3%) in the placebo group at three months, 207 (18%) in the treatment group and 179 (16%) in the placebo group at one year (<LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>). In another trial, losses to follow-up were 81 (15%) in the treatment group and 53 (10%) in the placebo group at three months, and 158 ( 30%) in the treatment group and 129 ( 25%) in the placebo group at one year (<LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>).</P>
<P>One trial was ended early for futility reasons (<LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>).</P>
<P>No serious imbalances in baseline prognostic factors were reported, although in one trial (<LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>), there were more lacunar strokes in the ancrod group (22% versus 13%) and in another trial (<LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>) there was slightly more milder strokes (Scandanavian Stroke Scale scores 30 to 39) in the control group (39% versus 34%).</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-01-11 15:00:27 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1 Fibrinogen depleting agents versus control</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Death or dependency at the end of follow-up</HEADING>
<P>Six trials (<LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>; <LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>) with a total of 5354 patients recorded death and disability in survivors but this was recorded at three months rather than at the end of follow-up, which lasted one year in four trials (<LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>; <LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>). There was a marginally significant trend for fewer patients being dead or dependent in the fibrinogen depleting agents group (1451/2662, 54.5%) than in the control group (1553/2692, 57.7%) (RR 0.95, 95% CI 0.90 to 0.99).There was no significant heterogeneity (I<SUP>2 </SUP>= 16%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>Two trials conducted in China using defibrase did not perform an ITT analysis. There were incomplete outcome data for 7% of patients (146/2244) in <LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK> and 13% (134/1053) in <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK> at three months. We, therefore, performed an ITT analysis using imputation (we used best-case and worst-case scenarios for imputation). The best-case scenario is that all participants with missing outcomes in the treatment group had good outcomes, and all those with missing outcomes in the control intervention group had poor outcomes (RR 0.86, 95% CI 0.76 to 0.97; I<SUP>2 </SUP>= 84% ); the worst-case scenario is the converse (RR 1.01, 95% CI 0.93 to 1.10; I<SUP>2 </SUP>= 65%). There was significant heterogeneity in both analyses. We performed a sensitivity analysis excluding these two studies, which resulted in no significant heterogeneity but also no significant efficacy (RR 0.96, 95% CI 0.90 to 1.02; I<SUP>2 </SUP>= 19%). These results are not shown in the forest plots.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Death from all causes at end of treatment period</HEADING>
<P>Five trials provided data on early deaths (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>; <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>). One trial provided data on the number of early deaths at one month rather than at the end of the treatment period but these data were included in the analysis (<LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>). During the scheduled treatment period, there was no difference in the proportion dead in the treatment group (55/774, 7%) compared with the control group (57/810, 7%) (RR 1.00, 95% CI 0.70 to 1.43). However, there was substantial heterogeneity (I<SUP>2 </SUP>= 61%) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Death from all causes at end of follow-up</HEADING>
<P>All eight trials provided data on death at the end of follow-up. The risk of death from all causes was higher in the treatment group (369/2502, 15%) than in the control group (349/2526, 14%), but the difference was not significant (RR 1.07, 95% CI 0.94 to 1.22). There was no significant heterogeneity (I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Any symptomatic intracranial haemorrhage at end of treatment period</HEADING>
<P>Symptomatic intracranial haemorrhages before the end of the treatment period were recorded in eight trials (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>; <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>; personal communication for <LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK> and <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>), but the events occurred in only five trials (<LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>; <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK>; <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>) and were more common in the treatment group (86/2689, 3%) than in the control group (36/2715, 1%), a significant difference (RR 2.42, 95% CI 1.65 to 3.56) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The absolute difference was 2% suggesting that there might be an extra 20 symptomatic intracranial haemorrhages for every 1000 patients treated.There was significant heterogeneity (I<SUP>2 </SUP>= 61%), which appeared to be largely due to a greater risk of intracranial haemorrhage in the ancrod studies (67/1196 (6%) in the active arm, RR 3.30) than in the defibrase studies (19/1493 in the active arm (1%), RR 1.14). We performed a sensitivity analysis excluding these two defibrase studies: symptomatic intracranial haemorrhages were also more common in the treatment group (67/1196, 6%) than in the control group (19/1208, 2%), a significant difference with no significant heterogeneity (RR 3.56, 95% CI 2.15 to 5.87, I<SUP>2 </SUP>= 21%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Any symptomatic intracranial haemorrhage at end of follow-up</HEADING>
<P>One trial reported two symptomatic subdural haemorrhages during the follow-up period, both of which occurred in the placebo group (<LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 Any intracranial haemorrhage detected on systematic repeat CT during treatment period</HEADING>
<P>Symptomatic intracranial haemorrhage is obviously the most clinically relevant measure of intracranial haemorrhage. However, it may also be susceptible to bias. For example, in trials where the doctor monitoring the patient was aware of the treatment allocation (either because the trial was open or because the treatment was associated with side effects which unblinded the doctor), the threshold for scanning a patient to look for an intracranial haemorrhage may be lower for those on fibrinogen depleting agents than for those in the control group. Haemorrhage detected by systematic neuroimaging (CT or MR) in all survivors at some point in the treatment period or by autopsy in those who died will be less susceptible to this sort of investigation bias. However, it may detect asymptomatic haemorrhages which have little impact on the long-term outcome and therefore be less clinically meaningful.</P>
<P>Five trials reported intracranial haemorrhage detected by repeat CT during the treatment period (within the first 72 hours after beginning the infusion in <LINK REF="STD-ASP-2009" TYPE="STUDY">ASP 2009</LINK>, on day 15 in the <LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK> trial, on day 10 in the <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK> trial, and on day seven to 10 in the <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK> and <LINK REF="STD-ESTAT-2006" TYPE="STUDY">ESTAT 2006</LINK> trials). In the <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK> trial, some survivors in one centre did not have a repeat CT scan and so, to prevent possible bias, all patients from this centre were omitted from this analysis in the trial report. Unfortunately, it did not report how many patients were excluded. For the purposes of our analysis, we have therefore assumed that patients from this centre did not have intracranial haemorrhage. This should not bias the risk ratio, provided the distribution of intracranial haemorrhages between treatment and control in this centre was the same as in other centres, but it does mean that the absolute risk of any intracranial haemorrhage is underestimated. Overall, 157/1186 (13%) of patients in the treatment group had a haemorrhage on repeat CT scanning compared with 80/1198 (7%) in control group (RR 1.98, 95% CI 1.54 to 2.56) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). If the point estimate is correct, it implies that fibrinogen depleting agents therapy might cause an extra 60 intracranial haemorrhages detected by repeat CT (including asymptomatic patients) for every 1000 patients treated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7 Recurrent stroke (ischaemic/unknown type) at end of treatment period</HEADING>
<P>Only one trial recorded the number of recurrent ischaemic strokes or recurrent strokes of unknown pathology (i.e. where no CT/MR scan was performed) during the treatment period, but no recurrence occurred (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.8 Recurrent stroke (ischaemic/unknown type) at end of follow-up</HEADING>
<P>Four trials (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>; <LINK REF="STD-RDTCI-2000" TYPE="STUDY">RDTCI 2000</LINK>; <LINK REF="STD-RDTCI_x002d_2-2005" TYPE="STUDY">RDTCI-2 2005</LINK>) reported this outcome during the follow-up period. There were fewer recurrences in the treatment group (62/1331, 5%) than in the control group (94/1343, 7%), the difference was significant (RR 0.67, 95% CI 0.49 to 0.92, 2P = 0.01).There was no significant heterogeneity (I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). Data on the severity of recurrent strokes or intracranial haemorrhages at the end of follow-up were not available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.9 Venous thrombotic events</HEADING>
<P>One trial (<LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>) collected data on thrombophlebitis, but we were not sure if DVT was looked for systematically in all survivors. It showed 10 events occurred in the ancrod group (10/248, 4%) and 17 in control patients (17/252, 6.7%), a non-significant difference. Two trials recorded pulmonary embolism (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>). Three events occurred in the ancrod group (3/503) and 12 in control patients (12/497), a significant result (RR 0.25, 95% CI 0.07 to 0.88, 2P = 0.03) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). Myocardial infarction was recorded in only one trial (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>) but no events occurred.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.10 Any stroke or symptomatic intracranial haemorrhage</HEADING>
<P>The overall effect of fibrinogen depleting agents on new intracranial events is best assessed by this composite outcome i.e. summing the outcomes from section (2) and (4). It is possible that these agents may reduce the risk of early or late recurrent ischaemic stroke but that this benefit is outweighed by an increase in intracranial haemorrhage. Data on this outcome at the end of the scheduled treatment period were only available from one trial (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>) but no events occurred.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.11 Major extracranial haemorrhage</HEADING>
<P>Three trials (<LINK REF="STD-Hossmann-1983" TYPE="STUDY">Hossmann 1983</LINK>; <LINK REF="STD-Olinger-1988" TYPE="STUDY">Olinger 1988</LINK>; <LINK REF="STD-AISS-1994" TYPE="STUDY">AISS 1994</LINK>) reported this outcome but no major extracranial haemorrhages occurred either during the treatment period or during follow-up. The overall risk was therefore less than 1%. Two retroperitoneal haemorrhages occurred in the placebo group (<LINK REF="STD-STAT-2000" TYPE="STUDY">STAT 2000</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2 Different agents</HEADING>
<P>The subgroup analyses of different agents showed no difference between defibrase and ancrod in their effects on death/dependency (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), death from all causes (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) and recurrent stroke (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) at the end of follow-up. However, defibrase appeared to be associated with a lower risk of symptomatic intracranial haemorrhage (RR 1.15 95% CI 0.60 to 2.20) than ancrod (RR 3.56, 95% CI 2.15 to 5.87) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3 Different treatment time from onset</HEADING>
<P>The subgroup analyses by time to treatment showed no difference in treatment effects on death/dependency (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) or death from all causes (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>) or intracranial haemorrhage (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>) between trials recruiting within three hours of stroke onset and those recruiting within six hours. However, there were limited data and different trials contributed to different time windows and, therefore, these results may not be reliable.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-01-11 15:00:35 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-01-11 15:00:31 +0000" MODIFIED_BY="Hazel Fraser">
<P>We have included eight trials involving 5701 patients in this review so far. The results show only a moderately significant difference for fewer dead or dependent patients (5% relative risk reduction) at the end of follow-up in the treatment group but this result was not robust in a worst-case sensitivity analysis. There were also fewer stroke recurrences in the treatment group (62/1331, 5%) than in the control group (94/1343, 7%) (RR 0.67, 95% CI 0.49 to 0.92). However, this should be interpreted cautiously as data were only available for about 50% of all patients randomised. Symptomatic intracranial haemorrhage in the treatment group was about double that in the control group (RR 2.42, 95% CI 1.65 to 3.56) and any intracranial haemorrhage detected by repeated CT scan (including asymptomatic intracranial haemorrhages) was higher in treatment group (RR 1.98, 95% CI 1.54 to 2.56). In absolute terms, for every 1000 patients treated in the acute phase, death or dependency would be avoided in about 30 people after three months and 20 symptomatic intracranial haemorrhages would be caused.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-01-11 15:00:35 +0000" MODIFIED_BY="Hazel Fraser">
<P>In short, treatment with these agents may reduce the risk of death or dependency or recurrence at the end of follow-up. This promising result needs to be confirmed in more studies. The results of the review are limited by the following factors.</P>
<OL>
<LI>Loss to follow-up or exclusions after randomisation meant that the result for the primary outcome was not robust in sensitivity analyses.</LI>
<LI>Some outcomes had limited data when compared with the total number of patients included in the trials, which may raise the issue of reporting bias.</LI>
<LI>The confidence intervals for death were wide and so it is not possible to exclude a significant excess in mortality with treatment.</LI>
<LI>It seemed that defibrase caused less intracranial haemorrhage than ancrod but this must be interpreted with caution because different types of patients were recruited into each group. For example, the defibrase trials excluded patients with atrial fibrillation whereas, the ancrod trials did not. Whether defibrase is really safer than ancrod would require direct randomised comparisons.</LI>
<LI>The lack of individual patient data and the limited number of trials meant that it was not possible to assess whether there were significant differences in treatment effect in important subgroups such as patients treated within three hours compared with those treated later (as is the case with thrombolysis), those with elevated baseline fibrinogen levels or who had the largest drop in fibrinogen with treatment who might benefit more, or between different agents.</LI>
<LI>The variation in the definition of dependency (different scores and different cut-offs) and the timing of its assessment in different trials which might affect its interpretation. Although the I<SUP>2</SUP> statistic for death or dependency was low, suggesting no major heterogeneity between trials, we believe this variation means the result should be interpreted cautiously.</LI>
</OL>
<P>For these reasons, the results of this review need to be interpreted cautiously although we believe that these agents are worthy of further study. The benefits of defibrinogenating agents appear to be smaller than the benefits of thrombolysis (<LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>) and are based on much fewer data. However, we are not aware of any randomised trials that directly compare thrombolysis with defibrinogenating agents.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-12-14 11:10:21 +0000" MODIFIED_BY="Hazel Fraser">
<P>The quality of reporting in general was good. Seven trials adequately concealed the randomisation sequence and blinded outcome assessment. Five trials performed an ITT analysis while two trials using defibrase did not.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-01-11 15:00:39 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-12-14 11:10:47 +0000" MODIFIED_BY="[Empty name]">
<P>The data from the trials included in this review indicate that, compared with control, fibrinogen depleting agents tested in patients with acute ischaemic stroke have a marginal effect in terms of death or dependency after follow-up of at least three months, and may reduce the risk of recurrent ischaemic stroke during the follow-up period. However, there was evidence of a significant increase of intracranial haemorrhage. In addition, these results are not statistically robust and so the evidence was still not strong enough to recommend routine use of fibrinogen depleting agents for the treatment of acute ischaemic stroke.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-01-11 15:00:39 +0000" MODIFIED_BY="[Empty name]">
<P>Further trials are needed to determine reliably whether there is worthwhile benefit, and if so, which categories of patients (within three hours of onset, hyperfibrinogenemia, different stroke subtypes according to the TOAST classification (<LINK REF="REF-Adams-1993" TYPE="REFERENCE">Adams 1993</LINK>), are a few examples) are most likely to benefit. In addition, at a methodological level, it is dangerous that researchers who take part in collaborative multicentre trials report their individual single-centre results separately.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-10-01 03:06:32 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Hazel Fraser for providing us with references to the relevant trials from the Cochrane Stroke Group Trials Register, Brenda Thomas for help to develop trial searching strategies and Professor Hideki Origasa for searching the Japanese literature, Dr Li He, Dr Le Zhang, Dr Zhao Han and other volunteers for searching Chinese journals, Professor Volker Hossmann, Dr David Levy and Dr David G Sherman for providing us with additional data of their trials.</P>
<P>If anyone knows of trials that we have omitted we would be grateful if they could contact Dr Ming Liu.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-01-10 14:40:13 +0000" MODIFIED_BY="Hazel Fraser">
<P>None known.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-10-01 03:09:08 +0100" MODIFIED_BY="[Empty name]">
<P>Zilong Hao: collected data, undertook searches, appraised the quality of papers; selected trials for inclusion, extracted data from papers. Data management: entered data into RevMan and checked the data and wrote the review.</P>
<P>Ming Liu: designed the review, collected data, developed the search strategy, undertook searches, appraised the quality of papers, selected trials for inclusion, contacted authors for additional data, extracted data from papers. Data management: entered data into RevMan, carried out analysis and interpretation of the data. Wrote the review.</P>
<P>Carl Counsell: designed and conducted the original review and commented on the manuscript of the updated review.,</P>
<P>Joanna Wardlaw: searched for trials, performed previous work that formed the basis of this review, provided general advice on the review and assisted with writing the review, and commented on drafts.</P>
<P>Sen Lin: collected data, undertook searches, appraised the quality of papers; selected trials for inclusion, extracted data from papers.</P>
<P>Xiaoling Zhao: collected data, undertook searches, appraised the quality of papers; selected trials for inclusion, extracted data from papers. Data management: entered data into RevMan and checked the data and commented on drafts for previous version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-12-14 11:16:24 +0000" MODIFIED_BY="[Empty name]">
<P>We only included randomised controlled trials comparing fibrinogen depleting agents with placebo or open control in patients with acute ischaemic stroke in this updated review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-AISS-1994" MODIFIED="2011-12-14 11:49:58 +0000" MODIFIED_BY="Hazel Fraser" NAME="AISS 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-12-14 11:49:19 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glas-Greenwalt P, Levy DE</AU>
<TI>Ancrod causes rapid and efficient activation of fibrinolysis in patients with acute stroke</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1995</YR>
<VL>73</VL>
<NO>6</NO>
<PG>1151</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-14 11:49:33 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jahnke H</AU>
<TI>Experimental ancrod (Arvin) for acute ischaemic stroke: nursing implications</TI>
<SO>Journal of Neuroscience Nursing</SO>
<YR>1991</YR>
<VL>23</VL>
<PG>386-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992211153"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-14 11:49:50 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ringelstein EB, Olinger CP</AU>
<TI>The Ancrod Ischaemic Stroke Study: study design and demographics with initial clinical data from the first 60 patients. A multicenter placebo-controlled double-blind trial</TI>
<SO>International Conference on Stroke. Geneva, Switzerland</SO>
<YR>1991</YR>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-14 11:49:58 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The Ancrod Stroke Study Investigators</AU>
<TI>Ancrod for the treatment of acute ischaemic brain infarction</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>1755-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994353427"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ASP-2009" MODIFIED="2011-12-14 11:51:02 +0000" MODIFIED_BY="[Empty name]" NAME="ASP 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-14 11:51:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy DE, del Zoppo GJ, Demaerschalk BM, Demchuk AM, Diener H-C, Howard G, et al</AU>
<TI>Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program</TI>
<SO>Stroke</SO>
<YR>2009</YR>
<VL>40</VL>
<PG>3796-803</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ESTAT-2006" MODIFIED="2011-12-14 11:51:18 +0000" MODIFIED_BY="[Empty name]" NAME="ESTAT 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-12-14 11:51:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ESTAT investigators</AU>
<TI>Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<PG>1871-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hossmann-1983" MODIFIED="2011-12-14 11:51:44 +0000" MODIFIED_BY="Hazel Fraser" NAME="Hossmann 1983" YEAR="1983">
<REFERENCE MODIFIED="2011-12-14 11:51:33 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hossmann V, Heiss WD, Bewermeyer H, Wiedemann G</AU>
<TI>Controlled trial of ancrod in ischaemic stroke</TI>
<SO>Archives of Neurology</SO>
<YR>1983</YR>
<VL>40</VL>
<PG>803-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1984051898"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-14 11:51:44 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hossmann V, Heiss WD, Bewermeyer H</AU>
<TI>Controlled trial of ancrod induced hypofibrinogenemia</TI>
<SO>Cerebral vascular disease 3. Proceedings of the 10th International Salzburg Conferrence.</SO>
<YR>1981</YR>
<PG>36-9</PG>
<ED>Meyer JS, Lechner H, Reivich M, Ott EO, Aranibar</ED>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olinger-1988" MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="Hazel Fraser" NAME="Olinger 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-12-14 11:52:16 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Olinger CP, Brott TG, Barsan WG, Hedges JR, Glas-Greenwalt P, Pollak VE, et al</AU>
<TI>Use of ancrod in acute or progressing ischaemic cerebral infarction</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1988</YR>
<VL>17</VL>
<PG>1208-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1989048552"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-14 11:52:29 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olinger CP, Brott TG, Barsan WG, Hedges JR, Glas-Greenwalt P, Pollak VE</AU>
<TI>Double-blind, randomised placebo-controlled study of ancrod as therapy for acute cerebral infarction</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19</VL>
<PG>133</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pollack VE, Glas-Greenwalt P, Olinger CP, Wadhwa NK</AU>
<TI>Ancrod, a safe thrombolytic agent, causes rapid thrombolysis in acute stroke (Abstract)</TI>
<SO>Clinical Research</SO>
<YR>1989</YR>
<VL>37</VL>
<PG>A549</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pollack VE, Glas-greenwalt P, Olinger CP, Wadhwa NK, Myre SA</AU>
<TI>Ancrod causes rapid thrombolysis in patients with acute stroke</TI>
<SO>American Journal of the Medical Sciences.</SO>
<YR>1990</YR>
<VL>299</VL>
<PG>319-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990247444"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RDTCI-2000" MODIFIED="2011-12-14 11:52:47 +0000" MODIFIED_BY="Hazel Fraser" NAME="RDTCI 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-14 11:52:47 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Cooperative Group for Reassessment of Defibrase, China</AU>
<TI>Reassessment of defibrase in treatment of cerebral infarction</TI>
<SO>Chinese Journal of Neurology</SO>
<YR>2000</YR>
<VL>33</VL>
<NO>5</NO>
<PG>263-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RDTCI_x002d_2-2005" MODIFIED="2012-01-09 20:35:01 +0000" MODIFIED_BY="[Empty name]" NAME="RDTCI-2 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-09 20:35:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Cooperative Group for Reassessment of Defibrase, China</AU>
<TI>Reassement of defibrase in treatment of cerebral infarction</TI>
<SO>Chinese Journal of Neurology</SO>
<YR>2005</YR>
<VL>38</VL>
<NO>1</NO>
<PG>11-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STAT-2000" MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="Hazel Fraser" NAME="STAT 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;Participants: Acute ischaemic stroke &amp;lt; 3 hrs&lt;br&gt;Intervention: Ancrod vs placebo (ancrod regimen designed to reduce plasma fibrinogen to the range of 40-70mg/dl for 5 days).&lt;br&gt;Outcomes: Disability (Barthel), death, neurological impairment, infarct volume on CT&lt;br&gt;Size: 460 patients&lt;br&gt;Date started: 1993&lt;br&gt;Completion date: Unknown&lt;br&gt;Additional centres sought: No&lt;br&gt;Funding: Knoll Pharmaceuticals&lt;br&gt;Principle investigator: Dr DE Levy, MD&lt;br&gt;Contact: DE Levy, MD, Knoll Pharmaceuticals, 99 Cherry Hill Road, Parsippany, New Jersey, 07054-0603, USA&lt;/p&gt;" NOTES_MODIFIED="2012-01-11 15:01:33 +0000" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy DE</AU>
<TI>Stroke Treatment with Ancrod Trial (STAT)</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>544</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-14 11:53:47 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherman D</AU>
<TI>STAT: Stroke Treatment with Ancrod Trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>189</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-14 11:54:08 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, et al</AU>
<TI>Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>18</NO>
<PG>2395-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-01-10 10:42:32 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cai-2000" MODIFIED="2011-12-14 12:01:06 +0000" MODIFIED_BY="[Empty name]" NAME="Cai 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-14 12:01:06 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cai SY, Zhang GL, Wang ZY, Zhang W</AU>
<TI>Clinical and experimental study of fibrinogen depleting agents in the treatment of acute cerebral infarction</TI>
<SO>Journal of Apoplexy and Nervous Diseases (Zhong Feng Yu Shen Jing Ji Bing Za Zhi)</SO>
<YR>2000</YR>
<VL>17</VL>
<NO>3</NO>
<PG>184</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1996" MODIFIED="2011-12-14 11:55:37 +0000" MODIFIED_BY="Hazel Fraser" NAME="Chen 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-12-14 11:55:37 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen QT</AU>
<TI>Clinical study of batroxobin (DF-521) in the treatment of acute cerebral infarction (translation from Chinese)</TI>
<SO>Journal of Apoplexy and Nervous Diseases (Zhong Feng Yu Shen Jing Ji Bing Za Zhi)</SO>
<YR>1996</YR>
<VL>13</VL>
<PG>213-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2000" MODIFIED="2011-12-14 11:55:21 +0000" MODIFIED_BY="Hazel Fraser" NAME="Chen 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-14 11:55:21 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen QT, Zhao YB, Zheng YW, Wang Y, Wu ZS, Jiang YJ, et al</AU>
<TI>A clinical trial of Batroxobin injection in the treatment of acute cerebral infarction</TI>
<SO>Journal of Apoplexy and Nervous Diseases (Zhong Feng Yu Shen Jing JI Bing Za Zhi)</SO>
<YR>2000</YR>
<VL>17</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CRG-1982" MODIFIED="2011-12-14 11:56:13 +0000" MODIFIED_BY="Hazel Fraser" NAME="CRG 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-12-14 11:56:13 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerebrovascular Research Group</AU>
<TI>China made defibrase in the treatment of cerebral thrombosis. a clinical controlled study</TI>
<SO>Bulletin of Hunan Medical College (Hunan Yi Ke Da Xue Xue Bao)</SO>
<YR>1982</YR>
<VL>7</VL>
<NO>2</NO>
<PG>163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cui-2000" MODIFIED="2011-07-10 06:54:47 +0100" MODIFIED_BY="[Empty name]" NAME="Cui 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-07-10 06:54:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cui W, Chang F, Zou Y</AU>
<TI>Clinical study of treatment on acute cerebral infarction with defibrase</TI>
<SO>Chinese General Practice</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>6</NO>
<PG>432-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2003" MODIFIED="2011-12-14 11:56:42 +0000" MODIFIED_BY="[Empty name]" NAME="Du 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-12-14 11:56:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du H, Zhang P, Qian F</AU>
<TI>Clinical effect of batroxobin in treatment of patients with acute cerebral infarction</TI>
<SO>Chinese Journal of Clinincal Pharmacy (Zhong Guo Lin Chuang Yao Xue Za Zhi)</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>4</NO>
<PG>210-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-2000" MODIFIED="2011-12-14 11:56:49 +0000" MODIFIED_BY="[Empty name]" NAME="Fan 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-14 11:56:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan W, Jin I, Wang X, Guo S, Zhang Y, Fei G</AU>
<TI>Efficacy of defibrase in double-blind treatment of acute cerebral infarction</TI>
<SO>Journal of Shanghai Medical University</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>5</NO>
<PG>413-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-2001" MODIFIED="2011-12-14 12:27:17 +0000" MODIFIED_BY="[Empty name]" NAME="Fan 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-12-14 12:27:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan XC, Zhang L, Huang XM</AU>
<TI>Clinical analysis of brinolase used in 50 cases of acute cerebral infarction</TI>
<SO>Chinese Journal of Practical Internal Medicine (Zhong Guo Shi Yong Nei Ke Za Zhi)</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>3</NO>
<PG>165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-1996" MODIFIED="2011-12-14 12:29:31 +0000" MODIFIED_BY="Hazel Fraser" NAME="Gao 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-12-14 12:29:31 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao BT, Shi TH, Bu BT, Wang HY</AU>
<TI>Observation on clinical efficacy of Tobishi Batroxobin in the treatment of cerebral infarction</TI>
<SO>Journal of Chinese New Agents (Zhong Guo Xin Yao Za Zhi)</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>3</NO>
<PG>194-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2008" MODIFIED="2011-12-14 11:58:15 +0000" MODIFIED_BY="[Empty name]" NAME="Guo 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-14 11:58:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo Y, Wang L, Tang B, Li F, Wang Q</AU>
<TI>Dynamic changes in fibrinogen levels of patients with acute cerebral infarction after taking defibrase</TI>
<SO>Neural Regeneration Research</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>5</NO>
<PG>513-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gusev-2006" MODIFIED="2011-12-14 11:58:32 +0000" MODIFIED_BY="[Empty name]" NAME="Gusev 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-12-14 11:58:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gusev EI, Skvortsova VI, Suslina ZA, Avakian GN, Martynov MI, Temirbaseva SL, et al</AU>
<TI>Batroxobin in patients with ischemic stroke in the carotid system (the multicenter study)</TI>
<SO>Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova</SO>
<YR>2006</YR>
<VL>106</VL>
<NO>8</NO>
<PG>31-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hao-1984" MODIFIED="2011-12-14 11:58:45 +0000" MODIFIED_BY="Hazel Fraser" NAME="Hao 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-12-14 11:58:45 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hao WX</AU>
<TI>Effect of an antithrombotic enzyme of Agkistrodon halys venom in the treatment of cerebral thrombosis. Report of 322 cases</TI>
<SO>Chung Hua Shen Ching Ching Shen Ko Tsa Chih</SO>
<YR>1984</YR>
<VL>17</VL>
<NO>4</NO>
<PG>223-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1985256694"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-1998" MODIFIED="2012-01-09 20:37:37 +0000" MODIFIED_BY="Hazel Fraser" NAME="He 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-01-09 20:37:37 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He BZ, Ge J, Wang PY, Tian FS</AU>
<TI>Clinical observation on batroxobin in progressive cerebral infarction</TI>
<SO>Emergency in China (Zhong Guo Ji Jiu Yi Xue)</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>12-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-1996" MODIFIED="2011-12-14 12:04:55 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-12-14 12:04:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang R, Fang Y, Su Z</AU>
<TI>Clinical report of 31 cases of acute cerebral infarction treated with snake venom svate-IV</TI>
<SO>Chinese Journal of Nervous and Mental Diseases (Zhong Guo Shen Jing Jing Shen Ji Bing Za Zhi)</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>6</NO>
<PG>378</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2000" MODIFIED="2011-12-14 11:59:46 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-14 11:59:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang HY, Lu XW, Zhang YP, Zhang AH</AU>
<TI>Observation on curative effect of senile acute cerebral infarction with batroxobin</TI>
<SO>Medical Journal of Trauma and Disability</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>2</NO>
<PG>27-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuang-1996" MODIFIED="2011-12-14 12:00:32 +0000" MODIFIED_BY="Hazel Fraser" NAME="Kuang 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-12-14 12:00:32 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuang P, Peng C, Tao Y, Yu S, Wu W, Lang S, et al</AU>
<TI>Batroxobin rapidly stops transient ischaemia with frequent Attacks. A randomised controlled multicenter study</TI>
<SO>Journal of Brain and Neurological Diseases (Nao Yu Shen Jing Ji Bing Za Zhi)</SO>
<YR>1996</YR>
<VL>4</VL>
<NO>2</NO>
<PG>65-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2000" MODIFIED="2011-12-14 12:00:38 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-14 12:00:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li QM, Wang Q, Tan L</AU>
<TI>Study of a double-blinded control trial in treating acute cerebral infarction with defibrase</TI>
<SO>Journal of Snake</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>4</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lian-1998" MODIFIED="2011-12-14 12:29:48 +0000" MODIFIED_BY="Hazel Fraser" NAME="Lian 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-12-14 12:29:48 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lian YJ, Fang SY, Nie QB, Wang WZ</AU>
<TI>The comparative study of clinical efficacy between DF-521 and routine agents</TI>
<SO>Journal of Apoplexy and Nervous Diseases</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>2</NO>
<PG>111-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2003" MODIFIED="2011-07-10 12:54:59 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-07-10 12:54:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu J, Yan SQ, Ji YS, Wu SJ, Kong FY</AU>
<TI>Reassessment of defibrase in treatment of cerebral infarction with double-blind and placebo-controlled clinical trial</TI>
<SO>Shanxi Medical Journal</SO>
<YR>2003</YR>
<VL>32</VL>
<PG>539-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mei-2000" MODIFIED="2011-12-14 12:05:43 +0000" MODIFIED_BY="[Empty name]" NAME="Mei 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-14 12:05:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mei YW, Deng XJ, Wei GR, Chen JX, Liu CQ, Xing HY, et al</AU>
<TI>Clinical analysis of 29 cases of acute cerebral infarction treated by defibrase</TI>
<SO>Journal of Snake</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>1</NO>
<PG>22-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qiang-1995" MODIFIED="2011-12-14 12:06:12 +0000" MODIFIED_BY="Hazel Fraser" NAME="Qiang 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-12-14 12:06:12 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qiang L, Lin J, Wu S, Yang Q, Qian C</AU>
<TI>Batroxobin in the treatment of cerebral infarction</TI>
<SO>Journal of Clinical Neurology (Lin Chuang Shen Jing Bing Xue Za Zhi)</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>1</NO>
<PG>55-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2000" MODIFIED="2011-12-14 12:06:20 +0000" MODIFIED_BY="[Empty name]" NAME="Sun 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-14 12:06:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun S, Yu Z, Wang S, Wang Y, Li W</AU>
<TI>A prospective randomized double-blind, controlled clinical trial of treatment of cerebral infarction with homemade defibrase</TI>
<SO>Heilonghiang Medicine and Pharmacy</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>33-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2002" MODIFIED="2011-07-10 12:59:03 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-07-10 12:59:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun S, Chen X, Yu Z</AU>
<TI>Clinical studies of defibrase in treating cerebral infarction</TI>
<SO>Chinese Journal of Practical Internal Medicine</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>10</NO>
<PG>593-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1999" MODIFIED="2010-01-09 02:41:40 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-09 02:41:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang QZ, Jiao XD, Xu Y</AU>
<TI>Clinical analysis of defibrase in treatment of cerebral infarction</TI>
<SO>Chinese Journal of Clinical Neurology</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>2</NO>
<PG>113-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1999a" MODIFIED="2010-01-09 02:45:32 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 1999a" YEAR="1999">
<REFERENCE MODIFIED="2010-01-09 02:45:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y</AU>
<TI>Observations of effect of defibrase in treatment of 30 cases with acute cerebral thrombosis</TI>
<SO>Chinese Journal of Critical Care Medicine</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>8</NO>
<PG>485</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" MODIFIED="2008-11-16 07:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-16 07:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang T, Chen Z</AU>
<TI>The effect of defibrase in the treatment of 35 patients with progressive cerebral infarction</TI>
<SO>Herald of Medicine (Yi YaoDao Bao)</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>2</NO>
<PG>84-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004" MODIFIED="2012-01-10 10:42:32 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-10 10:42:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang YZ, Song BS, Xu WH, et al</AU>
<TI>A randomized double-blind placebo-controlled study of defibrase in the treatment of cerebral infarction</TI>
<SO>Anhui Medical Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<PG>92-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2004" MODIFIED="2011-07-10 13:02:37 +0100" MODIFIED_BY="[Empty name]" NAME="Wei 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-07-10 13:02:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei CH, Zhu XC, Shi JF, Yang YK, Ma RY</AU>
<TI>Effects of defibrase on neurologic impairment in patients with acute cerebral infarction: a randomized, double-blind and controlled study at stage II</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>31</NO>
<PG>6834-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-1997" MODIFIED="2011-12-14 12:07:47 +0000" MODIFIED_BY="Hazel Fraser" NAME="Wu 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-12-14 12:07:47 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu RD, Gao L, Song ZH</AU>
<TI>Clinical study of batroxobin in the treatment of acute cerebral infarction</TI>
<SO>Journal of Brain and Nervous Diseases (Nao Yu Shen Jing Ji Bing Za Zhi)</SO>
<YR>1997</YR>
<VL>5</VL>
<NO>1</NO>
<PG>57-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xie-2003" MODIFIED="2011-07-10 13:04:20 +0100" MODIFIED_BY="[Empty name]" NAME="Xie 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-07-10 13:04:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xie LC, Wei LH, Guan JZ, Niu XY, Guo JH, Li XY</AU>
<TI>Effects of defibrase on acute cerebral infarction</TI>
<SO>Journal of Shanxi Medical University</SO>
<YR>2003</YR>
<VL>34</VL>
<PG>530-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2000" MODIFIED="2011-12-14 12:08:16 +0000" MODIFIED_BY="[Empty name]" NAME="Xu 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-14 12:08:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu W, Sun B</AU>
<TI>The curative effects of defibrase in the treatment of acute cerebral infarction</TI>
<SO>Journal of Snake</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>2</NO>
<PG>23-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yan-2001" MODIFIED="2011-12-13 14:17:47 +0000" MODIFIED_BY="[Empty name]" NAME="Yan 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-12-13 14:17:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yan SQ, Kong FY, Wang LF, Liang YE, Jia HY, Zhao XM</AU>
<TI>A double-blind controlled study of defibrase in treatment of cerebral infarction</TI>
<SO>Zhongfeng Yu Shenjing Jibing Zazhi</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>3</NO>
<PG>179-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2000" MODIFIED="2011-12-14 12:08:41 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-12-14 12:08:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang D, Cui Y</AU>
<TI>Clinical study of defibrase in the treatment of cerebral infarction</TI>
<SO>Journal of Snake</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>1</NO>
<PG>28-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2004" MODIFIED="2011-07-10 13:05:56 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-07-10 13:05:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang Q, Cheng OM, Peng GG, Dong WW</AU>
<TI>Effect of defibrase on hemorrheology in patients with cerebral infarction: randomized double-blinded placebo-controlled study</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>31</NO>
<PG>6836-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2000" MODIFIED="2010-01-09 03:28:21 +0000" MODIFIED_BY="[Empty name]" NAME="Yu 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-09 03:28:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu ZQ, Yang J, Xue H</AU>
<TI>Observation of clinical effect of defibrase in treatment of 50 senile cases with cerebral infarction</TI>
<SO>Chinese Journal of Critical Care Medicine</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>12</NO>
<PG>698</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2003" MODIFIED="2011-12-14 12:09:18 +0000" MODIFIED_BY="[Empty name]" NAME="Yu 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-12-14 12:09:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu NW, Yang YS, Xiao J</AU>
<TI>Observation of the effect of treating acute cerebral infarction of 53 patients with defibrase by random double-blind method and surveyed for 3 years</TI>
<SO>Journal of Brain and Nervous Diseases</SO>
<YR>2003</YR>
<VL>11</VL>
<PG>241-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1996" MODIFIED="2011-12-14 12:09:37 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-12-14 12:09:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang X, Zhang L, Wen L</AU>
<TI>Comparative study on the effectiveness of tobishi pure thrombolysase on acute cerebral infarction</TI>
<SO>Chinese Journal of Pharmacoepidemiology</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>1</NO>
<PG>9-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-11-16 06:12:33 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1998" MODIFIED="2010-01-09 03:48:52 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-01-09 03:48:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang RL, Fu XH, Zhang Y</AU>
<TI>Efficacy analysis of DF-521 on cerebral infarction through different ways</TI>
<SO>Chinese Journal of Practical Internal Medicine</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>10</NO>
<PG>614</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2001" MODIFIED="2010-01-09 03:36:09 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-09 03:36:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang JD, Wang J, Li CY</AU>
<TI>Change of t-PA, PAI and their clinical study before and after defibrase in treatment of acute cerebral infarction</TI>
<SO>Chinese Journal of Critical Care Medicine</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>9</NO>
<PG>540</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2002" MODIFIED="2010-01-09 03:38:11 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-09 03:38:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang M, Dai JL, Fang JH, Cao P, Sun J, Yu CQ</AU>
<TI>Defibrase in treatment of acute and chronic cerebral infarction</TI>
<SO>Journal of Bengbu Medical College</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>5</NO>
<PG>413-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-1999" MODIFIED="2011-12-14 12:10:36 +0000" MODIFIED_BY="[Empty name]" NAME="Zhao 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-12-14 12:10:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao Y, Zhao G, Chen Q, Li M, Cao M, Murong S, et al</AU>
<TI>A clinical study of acutase injection in the treatment of acute cerebral infarction</TI>
<SO>Chinese Journal of Clinical Pharmacology (Zhong Guo Lin Chuang Yao Li Xue Za Zhi)</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>4</NO>
<PG>246-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-12-14 12:11:26 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1999" MODIFIED="2011-12-14 12:11:10 +0000" MODIFIED_BY="Hazel Fraser" NAME="Li 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-12-14 12:11:10 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li BXY, Lang S, Zhang Z, Dong Q, Zhu K, Zhang Z, et al</AU>
<TI>Defibrase for the treatment of acute ischemic stroke</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>18 Suppl 1</NO>
<PG>I-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2010" MODIFIED="2011-12-14 12:11:26 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-12-14 12:11:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li YJ, Huang Y, Fu YG, et al</AU>
<TI>Defibrination on treatment of acute cerebral infarction of internal carotid artery system: a prospective randomized controlled trial</TI>
<SO>International Medicine and Health Guidance News</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>2</NO>
<PG>135-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-12-14 05:42:12 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams-1993" MODIFIED="2012-01-11 15:01:33 +0000" MODIFIED_BY="Hazel Fraser" NAME="Adams 1993" TYPE="JOURNAL_ARTICLE">
<AU>Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al</AU>
<TI>Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment</TI>
<SO>Stroke</SO>
<YR>1993</YR>
<VL>24</VL>
<PG>35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ATT-2002" NAME="ATT 2002" TYPE="JOURNAL_ARTICLE">
<AU>Antithrombotic Trialists' Collaboration</AU>
<TI>Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>324</VL>
<PG>71-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-1997" MODIFIED="2011-12-14 12:14:45 +0000" MODIFIED_BY="Hazel Fraser" NAME="Chen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Chen ZM, Sandercock P, Xie JX, Peto R, Collins R, Liu LS</AU>
<TI>Hospital management of acute ischemic stroke in China</TI>
<SO>Journal of Stroke and Cerebrovascular Diseases</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>361-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cina-2002" MODIFIED="2012-01-09 20:54:25 +0000" MODIFIED_BY="Hazel Fraser" NAME="Cina 2002" TYPE="COCHRANE_REVIEW">
<AU>Cina CS, Clase CM, Haynes RB</AU>
<TI>Carotid endarterectomy for symptomatic carotid stenosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-12-13 14:19:25 +0000" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2011-12-13 14:19:25 +0000" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD001081"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collins-1990" MODIFIED="2011-12-14 12:15:07 +0000" MODIFIED_BY="Hazel Fraser" NAME="Collins 1990" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al</AU>
<TI>Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>827-38</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990205389"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Donnan-2008" MODIFIED="2011-12-14 12:17:14 +0000" MODIFIED_BY="[Empty name]" NAME="Donnan 2008" TYPE="JOURNAL_ARTICLE">
<AU>Donnan GA, Fisher M, Macleod M, Davis SM</AU>
<TI>Stroke</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<PG>1612-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hacke-2008" MODIFIED="2011-12-14 12:19:07 +0000" MODIFIED_BY="[Empty name]" NAME="Hacke 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hacke W, Kaste M, Bluhmki E, Brozman M, Dvalos A, Guidetti D, et al</AU>
<TI>Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>359</VL>
<PG>1317-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Latallo-1983" MODIFIED="2011-12-14 12:19:22 +0000" MODIFIED_BY="Hazel Fraser" NAME="Latallo 1983" TYPE="JOURNAL_ARTICLE">
<AU>Latallo ZS</AU>
<TI>Retrospective study on complications and adverse effects of treatment with thrombinlike enzymes</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1983</YR>
<VL>50</VL>
<PG>604-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1984045573"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pollack-1990" MODIFIED="2011-12-14 12:20:29 +0000" MODIFIED_BY="Hazel Fraser" NAME="Pollack 1990" TYPE="JOURNAL_ARTICLE">
<AU>Pollack VE, Glas-Greenwalt P, Olinger CP, Wadhwa NK, Myre SA</AU>
<TI>Ancrod causes rapid thrombolysis in patients with acute stroke</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>1990</YR>
<VL>299</VL>
<PG>319-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990247444"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-12-13 15:43:38 +0000" MODIFIED_BY="Hazel Fraser" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherman-1996" MODIFIED="2012-01-10 11:54:04 +0000" MODIFIED_BY="Heather Maxwell" NAME="Sherman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Sherman D</AU>
<TI>STAT: Stroke Treatment with Ancrod Trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>189</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SPARCL-2006" MODIFIED="2011-12-14 12:14:09 +0000" MODIFIED_BY="[Empty name]" NAME="SPARCL 2006" TYPE="JOURNAL_ARTICLE">
<AU>The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators</AU>
<TI>High-dose atorvastatin after stroke or transient ischemic attack</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>549-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2009" MODIFIED="2011-12-13 14:19:14 +0000" MODIFIED_BY="[Empty name]" NAME="Wardlaw 2009" TYPE="COCHRANE_REVIEW">
<AU>Wardlaw JM, Murray V, Berge E, del Zoppo GJ</AU>
<TI>Thrombolysis for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-12-13 14:19:14 +0000" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2011-12-13 14:19:14 +0000" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000213"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-12-14 12:21:09 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Liu-1997" MODIFIED="2011-12-13 14:19:51 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 1997" TYPE="COCHRANE_REVIEW">
<AU>Liu M, Counsell C, Wardlaw J</AU>
<TI>Fibrinogen depleting agents in acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-12-13 14:19:51 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-13 14:19:51 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000091"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Liu-1998a" MODIFIED="2011-12-13 14:20:03 +0000" MODIFIED_BY="Hazel Fraser" NAME="Liu 1998a" TYPE="COCHRANE_REVIEW">
<AU>Liu M, Counsell C, Wardlaw J</AU>
<TI>Fibrinogen depleting agents in acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-12-13 14:20:03 +0000" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2011-12-13 14:20:03 +0000" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000091"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Liu-1998b" MODIFIED="2011-12-14 12:21:09 +0000" MODIFIED_BY="Hazel Fraser" NAME="Liu 1998b" TYPE="JOURNAL_ARTICLE">
<AU>Liu M, Counsell C, Wardlaw J, Sandercock P</AU>
<TI>A systematic review of randomized evidence for fibrinogen-depleting agents in acute ischaemic stroke</TI>
<SO>Journal of Stroke and Cerebrovascular Diseases</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>1</NO>
<PG>63-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2003" MODIFIED="2011-12-13 14:19:39 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2003" TYPE="COCHRANE_REVIEW">
<AU>Liu M, Counsell C, Zhao XL, Wardlaw J</AU>
<TI>Fibrinogen depleting agents for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-12-13 14:19:39 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-13 14:19:39 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000091"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-01-11 15:01:11 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-01-11 15:01:09 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-01-11 15:00:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AISS-1994">
<CHAR_METHODS MODIFIED="2011-12-14 11:17:25 +0000" MODIFIED_BY="[Empty name]">
<P>C: sequentially numbered identical containers<BR/>Doctor, patients, and assessor blinded (1 unblinded dosing supervisor was not involved in treatment or assessment)<BR/>Ex during trial: none<BR/>Losses to FU: 2 in Rx and 1 in control for Barthel Index</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-20 15:57:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: USA<BR/>132 patients<BR/>Age: mean 67 years (range 44 to 75 years)<BR/>Sex: 65% male<BR/>Moderate (SSS &lt; 40) ischaemic stroke<BR/>100% CT before entry<BR/>&lt; 6 hours from stroke onset<BR/>Comparability: slightly more lacunar stroke in Rx group (22% versus 13%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-11 15:00:43 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: ancrod 0.5 u/kg iv over 6 hours on day 1, followed by 0.15 to 0.24 u/kg depending on plasma fibrinogen level (target 70 to 100 mg/dL)<BR/>Control: placebo 250 mL saline iv<BR/>Duration: 7 days<BR/>Only 15/64 (23%) achieved the target fibrinogen level of &lt; 100 mg/dL within 6 hours of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-14 11:18:39 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death at 1 month, 1 year<BR/>Disability at 3 months (Barthel index &#8804; 90 or worse than pretreatment score)<BR/>Symptomatic intracranial haemorrhage<BR/>Intracranial haemorrhage in routine repeat CT (CT at 2 to 10 days)<BR/>Major extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-14 11:18:54 +0000" MODIFIED_BY="Hazel Fraser">
<P>FU: 12 months for death; 3 months for Barthel Index<BR/>Ex: coma, postoperative stroke, heart disease, renal or hepatic failure, bleeding tendency</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-11 15:00:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ASP-2009">
<CHAR_METHODS MODIFIED="2011-12-14 11:20:06 +0000" MODIFIED_BY="[Empty name]">
<P>C: identical-appearing vials were assigned by using an interactive voice response system</P>
<P>Patients and assessors blinded</P>
<P>Ex during trial: none</P>
<P>Losses to FU: 0 in Rx, 3 in control at 90 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-14 12:25:59 +0000" MODIFIED_BY="[Empty name]">
<P>500 patients</P>
<P>Age: mean 70.2 years in Rx group, mean 69.6 years in placebo group</P>
<P>Sex: 49.2% male</P>
<P>Ischaemic stroke with pretreatment NIHSS &#8807; 5 (pretreatment NIHSS 1a &gt; 2 were excluded)</P>
<P>100% CT or MRI before entry</P>
<P>&lt; 6 hours from stroke onset</P>
<P>Comparability: similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-11 15:00:49 +0000" MODIFIED_BY="[Empty name]">
<P>Rx: 0.5 IU/kg ancrod for 3 hours in patients with pretreatment fibrinogen levels &#8807; 200 mg/dL or 0.33 IU/kg ancrod for 2 hours in patients with pretreatment fibrinogen levels 100 to 199 mg/dL</P>
<P>Control: placebo</P>
<P>Duration: 2 or 3 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-14 06:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>Death at 90 days</P>
<P>Disability at 90 days (mRS )</P>
<P>Symptomatic intracerebral haemorrhage</P>
<P>Asymptomatic intracerebral haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-11 15:00:52 +0000" MODIFIED_BY="[Empty name]">
<P>FU: 90 days for death and disability</P>
<P>Ex: neuroimaging evidence of haemorrhage; coma; NIHSS &lt; 5; use or intended use of thrombolytic agent; previous stroke; blood pressure &gt; 185/105 mmHg; fibrinogen &lt; 100 mg/dL; intrinsic or extrinsic coagulation disorders; patients with medical condition not likely to survival through 90 days; previous exposure to ancrod or snake bites</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-11 15:00:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ESTAT-2006">
<CHAR_METHODS MODIFIED="2011-12-14 11:28:32 +0000" MODIFIED_BY="[Empty name]">
<P>C: sequentially numbered prepacks</P>
<P>Doctor, patients, and assessor blinded (1 unblinded dosing supervisor was not involved in treatment or assessment)</P>
<P>Ex during trial: none</P>
<P>Losses to FU: 4 in Rx group, 5 in control group at 3 months; 16 in Rx group, 13 in control group at 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-14 11:29:06 +0000" MODIFIED_BY="[Empty name]">
<P>Countries: European countries, Australia and Israel</P>
<P>1222 patients</P>
<P>Age: 68.5 years (range 20 to 95 years)</P>
<P>Sex: 60% male</P>
<P>Moderate (SSS &lt; 40) ischaemic stroke</P>
<P>100% CT before entry</P>
<P>&lt; 6 hours from stroke onset</P>
<P>Comparability: similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-11 15:00:56 +0000" MODIFIED_BY="[Empty name]">
<P>Rx: ancrod continuous 72-hour intravenous infusion, followed by daily single infusions lasting about 1 hour for 2 days, to reach and maintain a target fibrinogen concentration (1.2 to 2.1 &#956;mol/L)</P>
<P>Control: placebo</P>
<P>Duration: 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-14 11:29:57 +0000" MODIFIED_BY="[Empty name]">
<P>Death at 3 months, 12 months</P>
<P>Disability at 3 months (Barth Index &lt; 95 or worse than pretreatment score)</P>
<P>Symptomatic intracerebral haemorrhage</P>
<P>Asymptomatic intracerebral haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-14 11:30:24 +0000" MODIFIED_BY="[Empty name]">
<P>FU: 12 months for death; 3 months for disability</P>
<P>Ex: comatose, recent stroke, neurological deficit interfering with evaluation, recent surgery, recent thrombolytic therapy, severe high or low blood pressure, bleeding tendency, prior treatment with ancrod, very mild stroke (SSS &#8805; 40 at baseline)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-11 15:01:04 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Hossmann-1983">
<CHAR_METHODS>
<P>C: sequentially numbered, sealed, opaque envelopes <BR/>Patients and assessors blinded<BR/>Ex during trial: none<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 09:39:08 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: Germany<BR/>30 patients<BR/>Age: mean: 65 years (range 44 to 75 years)<BR/>Sex: 53% male<BR/>Ischaemic stroke<BR/>100% CT before entry<BR/>&lt; 48 hours from stroke onset<BR/>Comparability: age, sex and pre-Rx neurological deficit similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-11 15:01:01 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: ancrod 1 u/kg subcutaneous injection/day until fibrinogen level 100 to 130 mg/dL, then variable dose to keep fibrinogen 100 to 130 mg/dL<BR/>Control: open<BR/>Duration: 14 days<BR/>Both groups: 10% LMWD 500 mL/day iv for 10 days and 20% mannitol 250 mL/day iv for 5 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-11 15:01:04 +0000" MODIFIED_BY="Heather Maxwell">
<P>Death at 2 weeks, 12 months<BR/>Symptomatic haemorrhage<BR/>Intracranial haemorrhage on routine repeat CT at 15 days<BR/>Recurrent ischaemic/unknown stroke<BR/>Major extracranial haemorrhage<BR/>Pulmonary embolism<BR/>MI<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 09:41:26 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 12 months<BR/>Ex: recent MI, severe high blood pressure, hepatic or renal insufficiency, bleeding tendency</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-11 15:01:05 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Olinger-1988">
<CHAR_METHODS MODIFIED="2008-08-21 09:40:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>C: unclear, placebo controlled trial<BR/>Doctor, patients, and assessor blinded<BR/>Ex during trial: ? none<BR/>Losses to FU: ? none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 09:40:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: USA<BR/>20 patients<BR/>Age: 30 to 80 years<BR/>Sex: unknown<BR/>Ischaemic stroke<BR/>100% CT before entry<BR/>? time from stroke onset<BR/>? comparability of groups</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-11 15:01:05 +0000" MODIFIED_BY="Hazel Fraser">
<P>Rx: ancrod 0.5 u/kg over 6 hours then iv 12 to 24 hourly infusion according to fibrinogen level (target 100 mg/dL)<BR/>Control: placebo (saline)<BR/>Duration: 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death at 7 days, 3 months<BR/>Symptomatic intracranial haemorrhage<BR/>Major extracranial haemorrhage<BR/>Recurrent ischaemic/unknown stroke</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 09:41:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 90 days<BR/>Ex: comatose, recent MI, severe high blood pressure, renal or hepatic failure, bleeding tendency.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-14 12:26:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RDTCI-2000">
<CHAR_METHODS MODIFIED="2011-12-14 11:32:25 +0000" MODIFIED_BY="[Empty name]">
<P>C: sequentially numbered identical containers<BR/>Doctor, patients, and assessor blinded<BR/>Ex during trial: ? none<BR/>Losses to FU: 207 in Rx group and 179 in placebo group at 1 year; 88 in Rx group and 58 in placebo group at 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 09:42:09 +0100" MODIFIED_BY="Hazel Fraser">
<P>Country: China<BR/>2244 patients<BR/>Age: mean 62 years (range 35 to 80 years)<BR/>Sex: 60% male<BR/>Moderate cerebral infarction<BR/>100% CT before entry<BR/>&lt; 24 hours from stroke onset<BR/>Comparability: age, sex similar between groups<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 09:43:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: defibrase 10 U iv on day 1, 5 U on day 3 and day 5<BR/>Control: placebo<BR/>Duration: 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 09:42:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death at 3 month, 1 year; ADL at 3 months<BR/>Neurological deficit scale at 2 weeks<BR/>Recurrent stroke at 1 year<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-14 12:26:16 +0000" MODIFIED_BY="Hazel Fraser">
<P>FU: 12 months for death; 3 months for ADL<BR/>Ex: bleeding tendency; pregnant; hypersensitivity; used fibrinolytic or defibrase within 1 week; heart, renal or hepatic failure; atrial fibrillation; severe high blood pressure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-14 12:26:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RDTCI_x002d_2-2005">
<CHAR_METHODS MODIFIED="2011-12-14 11:33:50 +0000" MODIFIED_BY="[Empty name]">
<P>C: sequentially numbered identical containers</P>
<P>Doctor, patients and assessors blinded</P>
<P>Ex during trial: ? none</P>
<P>Losses to FU: 81 in Rx group and 53 in placebo group at 3 months; 158 in Rx group and 129 in control group at 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-14 11:35:02 +0000" MODIFIED_BY="[Empty name]">
<P>Country: China</P>
<P>1053 patients</P>
<P>Age: mean 62 years in Rx group, mean 62 years in placebo group</P>
<P>Sex: 63% male</P>
<P>Moderate cerebral infarction</P>
<P>100% CT before entry</P>
<P>&lt; 12 hours from stroke onset</P>
<P>Comparability: age, sex, weight, mean blood pressure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-07 18:33:05 +0000" MODIFIED_BY="[Empty name]">
<P>Rx: defibrase 15 U iv on day 1, 5 U on day 3, day 5 and day 7</P>
<P>Control: placebo</P>
<P>Duration: 9 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-14 11:34:26 +0000" MODIFIED_BY="[Empty name]">
<P>Death at 3 months, 1 year</P>
<P>Dependency at 3 months (Barthel Index &lt; 95)</P>
<P>Neurological deficit scale at 2 weeks</P>
<P>Recurrent stroke at 1 year</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-14 12:26:26 +0000" MODIFIED_BY="[Empty name]">
<P>FU: 12 months for death; 3 months for ADL<BR/>Ex: bleeding tendency; pregnant; hypersensitivity; used fibrinolytic or defibrase within one week; heart, renal or hepatic failure; atrial fibrillation; severe high blood pressure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-14 11:36:17 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-STAT-2000">
<CHAR_METHODS MODIFIED="2011-12-14 11:35:45 +0000" MODIFIED_BY="Hazel Fraser">
<P>C: sequentially numbered identical containers<BR/>Doctor, patients, and assessor blinded (1 unblinded dosing supervisor was not involved in treatment or assessment)<BR/>Ex during trial: none<BR/>Losses to FU: 4 in Rx group, 1 in control group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 09:43:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>Countries: USA and Canada<BR/>500 patients<BR/>Age: mean 73 years (range 34 to 98 years)<BR/>Sex: 51% male<BR/>Moderate (SSS &lt; 40) ischaemic stroke<BR/>% CT before entry: unknown<BR/>&lt; 3 hours from stroke onset<BR/>Comparability: slightly more milder stroke (SSS scores 30 to 39) in control group (39% versus 34%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 09:44:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: ancrod 0.167 IU/kg iv per hour for over 72 hours, followed by 0.125 and 0.082 IU/kg over 1 hour at 96 and 120 hours depending on plasma fibrinogen level (target 1.18 to 2.03 micromol/L)<BR/>Control: placebo (identical-appearing supplies with saline) iv<BR/>Duration: 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-14 11:36:17 +0000" MODIFIED_BY="Hazel Fraser">
<P>Death at 3 month<BR/>Disability at 3 months (Barthel index &lt; 95 or worse than pretreatment score)<BR/>Symptomatic intracranial haemorrhage<BR/>Asymptomatic Intracranial haemorrhage/extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 09:44:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>FU: 90 days<BR/>Ex: comatose, recent stroke, neurological deficit interfering with evaluation, recent surgery, recent thrombolytic therapy, severe high or low blood pressure, bleeding tendency, prior treatment with ancrod</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL: activities of daily living<BR/>C: concealment of allocation<BR/>CT: computerised tomography<BR/>Ex: exclusion<BR/>FU: follow-up<BR/>ITT: intention-to-treat<BR/>iv: intravenous<BR/>LMWD: low molecular weight dextran<BR/>MI: myocardial infarction<BR/>MRI: magnetic resonance imaging<BR/>mRS: modified Rankin Scale<BR/>NIHSS: National Institutes of Health Stroke Scale<BR/>Rx: treatment<BR/>SSS: Scandinavian Stroke Scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-01-10 14:54:16 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:25:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cai-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:25:12 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:42:43 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Chen-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:42:43 +0000" MODIFIED_BY="Hazel Fraser">
<P>Confounded (batroxobin versus LMWD)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:25:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:25:21 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-21 09:44:51 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-CRG-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-21 09:44:51 +0100" MODIFIED_BY="Hazel Fraser">
<P>Non-random allocation based on patient preference; confounded (defibrase versus at least 3 of the following drugs: vasodilators, antiplatelet agents, dextran, Chinese medicine, acupuncture etc)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:43:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cui-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:43:08 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:25:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:25:28 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:43:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fan-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:43:13 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:25:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fan-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:25:33 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:25:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gao-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:25:37 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-10 07:09:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-10 07:09:25 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (laboratory data)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:25:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gusev-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:25:43 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-10 14:54:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hao-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-10 14:54:16 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded (antithrombotic enzymes of <I>Agkistrodon halys</I> venom versus LMWD)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:25:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-He-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:25:47 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:43:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:43:47 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded (svate versus batroxobin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:25:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:25:51 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-21 09:45:08 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Kuang-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-21 09:45:08 +0100" MODIFIED_BY="Hazel Fraser">
<P>Batroxobin in the treatment of transient ischaemic attacks; confounded (batroxobin versus conventional treatment including dextran, Chinese medicine, antiplatelet agents, calcium antagonists, free radical scavengers etc)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:44:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:44:06 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:25:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lian-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:25:58 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:44:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:44:10 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:44:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mei-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:44:13 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-20 15:38:36 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Qiang-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-20 15:38:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>Confounded (batroxobin versus a Chinese medicine)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:44:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:44:18 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:44:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:44:21 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:44:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:44:27 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded (defibrase versus dextran plus dan shen)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-09 11:46:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-1999a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-09 11:46:56 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded (defibrase versus ahylsantinfarctase)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:44:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:44:38 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded (defibrase versus ozagrel)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:44:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:44:42 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:44:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wei-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:44:45 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:26:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:26:06 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:44:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xie-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:44:54 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-10 07:09:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-10 07:09:34 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (laboratory data)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:45:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yan-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:45:00 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:45:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:45:07 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded (defibrase versus dextran plus dan shen)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:45:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:45:10 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:26:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:26:09 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:45:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:45:17 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre results from a multicentre trial included in this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-26 14:24:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-26 14:24:31 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-09 11:49:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-09 11:49:04 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of iv administration of batroxobin with intra-carotid artery injection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:45:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:45:30 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded (defibrase versus xanthinol nicotinate )</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 11:45:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 11:45:34 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded (defibrase versus ligustrazine)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-05 13:26:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-05 13:26:14 +0000" MODIFIED_BY="[Empty name]">
<P>No relevant outcome recorded (only impairment measured)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>iv: intravenous<BR/>LMWD: low molecular weight dextran</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-01-11 15:01:11 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2011-10-04 07:46:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-1999">
<CHAR_METHODS MODIFIED="2011-10-04 07:46:21 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS MODIFIED="2011-10-04 07:46:16 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_INTERVENTIONS MODIFIED="2011-10-04 07:46:15 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_OUTCOMES MODIFIED="2011-10-04 07:46:14 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2011-10-04 07:46:45 +0100" MODIFIED_BY="[Empty name]">
<P>No available information</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-12-14 12:26:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2010">
<CHAR_METHODS MODIFIED="2011-07-17 03:22:00 +0100" MODIFIED_BY="[Empty name]">
<P>C: Envelope<BR/>Patients, and assessor blinded (one unblinded doctor was not involved in treatment or assessment)<BR/>Ex during trial: none<BR/>Losses to FU: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-14 12:26:48 +0000" MODIFIED_BY="[Empty name]">
<P>Countries: China<BR/>150 patients<BR/>Age: unknown<BR/>Sex: unknown<BR/>Moderate (mean NIHSS 7) ischaemic stroke<BR/>% CT before entry: unknown<BR/>6 to 24 hours from stroke onset<BR/>Comparability: similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-14 11:46:25 +0000" MODIFIED_BY="[Empty name]">
<P>Rx: batroxobin 10 U iv on day 1, 5 U on day 3 and day 5<BR/>Control: placebo<BR/>Duration: 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-14 11:46:55 +0000" MODIFIED_BY="[Empty name]">
<P>Death at 3, 6 months<BR/>Disability at 3, 6 months<BR/>Neurological deficit scale at 2 weeks<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-14 12:26:53 +0000" MODIFIED_BY="[Empty name]">
<P>Ex: haemorrhagic infarction; platelet &lt; 100*10<SUP>9</SUP>/mm<SUP>3</SUP> or fibrinogen &lt; 1g/L; bleeding tendency; pregnant; recent surgery or trauma; used fibrinolytic or defibrase within 2 weeks; heart, renal or hepatic failure; shock or severe high blood pressure</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>C: concealment of allocation<BR/>CT: computerised tomography<BR/>Ex: exclusion<BR/>FU: follow-up<BR/>iv: intravenous<BR/>NIHSS: National Institutes of Health Stroke Scale<BR/>Rx: treatment<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-12-14 05:42:12 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-12-14 12:26:32 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-11-20 02:18:42 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 01:54:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AISS-1994">
<DESCRIPTION>
<P>Did not report</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:02:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ASP-2009">
<DESCRIPTION>
<P>Computer-generated codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:05:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESTAT-2006">
<DESCRIPTION>
<P>Computer-generated codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:12:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hossmann-1983">
<DESCRIPTION>
<P>Did not report</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:13:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olinger-1988">
<DESCRIPTION>
<P>Did not report</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:18:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RDTCI-2000">
<DESCRIPTION>
<P>Computer-generated codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:15:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RDTCI_x002d_2-2005">
<DESCRIPTION>
<P>Computer-generated codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:18:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STAT-2000">
<DESCRIPTION>
<P>Computer-generated codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-12-14 11:31:22 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 01:55:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AISS-1994">
<DESCRIPTION>
<P>Sequentially numbered identical containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:03:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ASP-2009">
<DESCRIPTION>
<P>Identical-appearing vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:05:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESTAT-2006">
<DESCRIPTION>
<P>Sequentially numbered prepacks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 11:31:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hossmann-1983">
<DESCRIPTION>
<P>Sequentially numbered, sealed, opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:13:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olinger-1988">
<DESCRIPTION>
<P>Did not report</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:18:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RDTCI-2000">
<DESCRIPTION>
<P>Sequentially numbered identical containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:15:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RDTCI_x002d_2-2005">
<DESCRIPTION>
<P>Sequentially numbered identical containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-20 02:18:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STAT-2000">
<DESCRIPTION>
<P>Sequentially numbered identical containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-12-14 12:26:32 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-20 01:55:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AISS-1994">
<DESCRIPTION>
<P>Doctor, patients, and assessor blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-20 02:03:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ASP-2009">
<DESCRIPTION>
<P>Patients and assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-20 02:06:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESTAT-2006">
<DESCRIPTION>
<P>Doctor, patients, and assessor blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-20 02:12:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hossmann-1983">
<DESCRIPTION>
<P>Patients and assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-20 02:13:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olinger-1988">
<DESCRIPTION>
<P>Doctor, patients, and assessor blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-12-14 12:26:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RDTCI-2000">
<DESCRIPTION>
<P>Doctor, patients and assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-12-14 12:26:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RDTCI_x002d_2-2005">
<DESCRIPTION>
<P>Doctor, patients and assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-20 02:19:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STAT-2000">
<DESCRIPTION>
<P>Doctor, patients, and assessor blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-12-14 11:36:35 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-14 11:19:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AISS-1994">
<DESCRIPTION>
<P>No exclusions after randomisation or losses to follow-up were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-14 11:27:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ASP-2009">
<DESCRIPTION>
<P>ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-14 11:30:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESTAT-2006">
<DESCRIPTION>
<P>ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-14 11:31:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hossmann-1983">
<DESCRIPTION>
<P>ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-14 11:32:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olinger-1988">
<DESCRIPTION>
<P>No exclusions after randomisation or losses to follow-up were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-14 11:33:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-RDTCI-2000">
<DESCRIPTION>
<P>Per-protocol analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-14 11:35:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-RDTCI_x002d_2-2005">
<DESCRIPTION>
<P>Per-protocol analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-14 11:36:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-STAT-2000">
<DESCRIPTION>
<P>ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-12-14 11:36:37 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 11:19:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AISS-1994">
<DESCRIPTION>
<P>The study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 11:27:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ASP-2009">
<DESCRIPTION>
<P>No obvious selective reporting was found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 11:30:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ESTAT-2006">
<DESCRIPTION>
<P>No obvious selective reporting was found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-16 08:28:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hossmann-1983">
<DESCRIPTION>
<P>The study protocol was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 11:32:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olinger-1988">
<DESCRIPTION>
<P>The study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 11:33:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RDTCI-2000">
<DESCRIPTION>
<P>The study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 11:35:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RDTCI_x002d_2-2005">
<DESCRIPTION>
<P>The study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 11:36:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-STAT-2000">
<DESCRIPTION>
<P>The study protocol was not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-12-14 11:27:55 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-19 09:46:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AISS-1994">
<DESCRIPTION>
<P>None known</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 11:27:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ASP-2009">
<DESCRIPTION>
<P>Ended early for futility reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-19 09:46:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ESTAT-2006">
<DESCRIPTION>
<P>None known</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-19 09:46:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hossmann-1983">
<DESCRIPTION>
<P>None known</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-19 09:46:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olinger-1988">
<DESCRIPTION>
<P>None known</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-19 09:47:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RDTCI-2000">
<DESCRIPTION>
<P>None known</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-19 09:46:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RDTCI_x002d_2-2005">
<DESCRIPTION>
<P>None known</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-19 09:47:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-STAT-2000">
<DESCRIPTION>
<P>None known</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-10-30 14:34:09 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-10-30 14:32:35 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Fibrinogen depleting agents versus control</NAME>
<DICH_OUTCOME CHI2="5.980647904572218" CI_END="0.9910242361605146" CI_START="0.9014135989322622" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9451575124531073" ESTIMABLE="YES" EVENTS_1="1451" EVENTS_2="1553" I2="16.39701785190382" I2_Q="100.0" ID="CMP-001.01" LOG_CI_END="-0.003915724422830328" LOG_CI_START="-0.04507589434947455" LOG_EFFECT_SIZE="-0.02449580938615243" METHOD="MH" MODIFIED="2013-10-30 14:32:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3081067978633595" P_Q="0.0" P_Z="0.01965435363548247" Q="8.23665683301619E-32" RANDOM="NO" SCALE="3.37" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2662" TOTAL_2="2692" WEIGHT="100.0" Z="2.3328817278734366">
<NAME>Death or dependency at the end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0183366746189295" CI_START="0.55028101200679" EFFECT_SIZE="0.7485795454545454" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="0.007891384833885655" LOG_CI_START="-0.25941547269301696" LOG_EFFECT_SIZE="-0.12576204392956564" ORDER="11035" O_E="0.0" SE="0.15701737130158747" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.024654454890460583" WEIGHT="2.7646888923644473"/>
<DICH_DATA CI_END="1.1133104537895433" CI_START="0.8451126889341236" EFFECT_SIZE="0.9699859747545582" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="155" LOG_CI_END="0.046616287036467224" LOG_CI_START="-0.07308537753642849" LOG_EFFECT_SIZE="-0.013234545249980623" MODIFIED="2009-12-09 01:59:38 +0000" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.07031335030291481" STUDY_ID="STD-ASP-2009" TOTAL_1="253" TOTAL_2="247" VAR="0.00494396723082041" WEIGHT="10.164119523194232"/>
<DICH_DATA CI_END="1.0971001087027665" CI_START="0.9071227236069508" EFFECT_SIZE="0.9975993377483444" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="360" LOG_CI_END="0.04024625808843265" LOG_CI_START="-0.042333953755990965" LOG_EFFECT_SIZE="-0.0010438478337791534" MODIFIED="2008-08-30 07:23:20 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.04850802521605576" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.0023530285103615014" WEIGHT="23.059813040445686"/>
<DICH_DATA CI_END="1.0474505592190828" CI_START="0.8898612284001511" EFFECT_SIZE="0.9654458251580553" ESTIMABLE="YES" EVENTS_1="544" EVENTS_2="556" LOG_CI_END="0.020133532960459288" LOG_CI_START="-0.050677715196790055" LOG_EFFECT_SIZE="-0.015272091118165373" MODIFIED="2009-12-05 05:56:53 +0000" MODIFIED_BY="[Empty name]" ORDER="11036" O_E="0.0" SE="0.041594877688899794" STUDY_ID="STD-RDTCI-2000" TOTAL_1="1056" TOTAL_2="1042" VAR="0.001730133849954534" WEIGHT="36.2677634393014"/>
<DICH_DATA CI_END="0.9799187616985338" CI_START="0.7734862674089638" EFFECT_SIZE="0.8706053671728728" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="275" LOG_CI_END="-0.008809927173292919" LOG_CI_START="-0.11154739242544331" LOG_EFFECT_SIZE="-0.06017865979936811" MODIFIED="2009-12-09 01:49:02 +0000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.06034849564776804" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="437" TOTAL_2="465" VAR="0.003641940926948678" WEIGHT="17.266135374856088"/>
<DICH_DATA CI_END="1.0452144319822532" CI_START="0.7925429826337423" EFFECT_SIZE="0.9101523847219474" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="163" LOG_CI_END="0.019205397694193393" LOG_CI_START="-0.10097717502257912" LOG_EFFECT_SIZE="-0.040885888664192876" ORDER="11037" O_E="0.0" SE="0.07059583812716176" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.004983772360876427" WEIGHT="10.477479729838164"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.711062730496224" CI_END="1.4315312678518703" CI_START="0.7033023962802826" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0033939261478373" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="57" I2="61.094856768115754" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.1558008384262338" LOG_CI_START="-0.15285790286310325" LOG_EFFECT_SIZE="0.0014714677815652912" METHOD="MH" MODIFIED="2013-10-30 14:22:06 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.05237635246530703" P_Q="1.0" P_Z="0.9850904324150194" Q="0.0" RANDOM="NO" SCALE="364.36" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="774" TOTAL_2="810" WEIGHT="100.0" Z="0.018687459452674533">
<NAME>Death from all causes at end of treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1061499196143392" CI_START="0.09185152997653652" EFFECT_SIZE="0.31875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.04381399211227478" LOG_CI_START="-1.036913605228252" LOG_EFFECT_SIZE="-0.49654980655798847" ORDER="11038" O_E="0.0" SE="0.6348247403657108" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.40300245098039217" WEIGHT="17.332665532504404"/>
<DICH_DATA CI_END="1.7491265621242627" CI_START="0.09147422688823888" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.24282123500387298" LOG_CI_START="-1.038701252347948" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="11039" O_E="0.0" SE="0.752772652709081" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.5666666666666667" WEIGHT="8.937155665197583"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11040" O_E="0.0" SE="0.0" STUDY_ID="STD-Olinger-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.949045120027262" CI_START="0.9290362650429744" EFFECT_SIZE="1.6552250190694127" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="18" LOG_CI_END="0.4696814172547343" LOG_CI_START="-0.03196733293784381" LOG_EFFECT_SIZE="0.21885704215844523" MODIFIED="2009-12-09 06:25:28 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.2946709590644824" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="437" TOTAL_2="465" VAR="0.08683097411598185" WEIGHT="31.175018386893207"/>
<DICH_DATA CI_END="1.6165520447519859" CI_START="0.5366991492767743" EFFECT_SIZE="0.9314516129032258" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.20858969124559457" LOG_CI_START="-0.2702690931137385" LOG_EFFECT_SIZE="-0.03083970093407198" ORDER="11041" O_E="0.0" SE="0.281284020321884" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.07912070008844203" WEIGHT="42.555160415404806"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.038250688276274" CI_END="1.2225148745514094" CI_START="0.9382156135552207" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0709727088528607" ESTIMABLE="YES" EVENTS_1="369" EVENTS_2="349" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.08725415196440889" LOG_CI_START="-0.02769734390596551" LOG_EFFECT_SIZE="0.02977840402922171" METHOD="MH" MODIFIED="2013-10-30 14:22:20 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5389167084378346" P_Q="1.0" P_Z="0.30988432712538416" Q="0.0" RANDOM="NO" SCALE="28.29" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2502" TOTAL_2="2526" WEIGHT="100.0" Z="1.0154648092648066">
<NAME>Death from all causes at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3495805044228693" CI_START="0.27313854028828644" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.1301987959572369" LOG_CI_START="-0.5636170158851276" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="11042" O_E="0.0" SE="0.4075508423198635" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.16609768907563024" WEIGHT="3.9147316821464786"/>
<DICH_DATA CI_END="1.6859512637023153" CI_START="0.7204074106356355" EFFECT_SIZE="1.102076124567474" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="34" LOG_CI_END="0.22684501618962832" LOG_CI_START="-0.14242182835998562" LOG_EFFECT_SIZE="0.042211593914821335" MODIFIED="2009-12-09 03:04:04 +0000" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.21690917238880375" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="0.04704958906639579" WEIGHT="10.000391799811865"/>
<DICH_DATA CI_END="1.448305956053406" CI_START="0.9604042196684184" EFFECT_SIZE="1.1793893129770991" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="131" LOG_CI_END="0.16086031668828346" LOG_CI_START="-0.017545940478105128" LOG_EFFECT_SIZE="0.07165718810508916" MODIFIED="2008-08-30 07:27:18 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.10479671858475248" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.010982352226131807" WEIGHT="37.342634211331"/>
<DICH_DATA CI_END="1.6359269307575819" CI_START="0.34384176299335795" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.21376390185519178" LOG_CI_START="-0.4636413750717917" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="11043" O_E="0.0" SE="0.39791121287711073" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.15833333333333333" WEIGHT="2.3068954555506034"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11044" O_E="0.0" SE="0.0" STUDY_ID="STD-Olinger-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2409711667682781" CI_START="0.6558163998003659" EFFECT_SIZE="0.9021359336851801" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="73" LOG_CI_END="0.09376169104030672" LOG_CI_START="-0.18321772726142432" LOG_EFFECT_SIZE="-0.044728018110558786" MODIFIED="2008-11-29 15:54:26 +0000" MODIFIED_BY="[Empty name]" ORDER="11045" O_E="0.0" SE="0.1626990813806697" STUDY_ID="STD-RDTCI-2000" TOTAL_1="937" TOTAL_2="921" VAR="0.026470991082113787" WEIGHT="21.23169484057008"/>
<DICH_DATA CI_END="1.9283323694921612" CI_START="0.7651720374795907" EFFECT_SIZE="1.2147040825246962" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="31" LOG_CI_END="0.2851818914941178" LOG_CI_START="-0.1162409092540025" LOG_EFFECT_SIZE="0.08447049112005764" MODIFIED="2008-11-29 15:29:24 +0000" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.2357977402343567" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="369" TOTAL_2="397" VAR="0.05560057429962916" WEIGHT="8.612459894270023"/>
<DICH_DATA CI_END="1.5057552708909716" CI_START="0.8090371039065934" EFFECT_SIZE="1.103726362625139" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="58" LOG_CI_END="0.1777543920915685" LOG_CI_START="-0.09203156039962408" LOG_EFFECT_SIZE="0.042861415845972244" ORDER="11046" O_E="0.0" SE="0.15847360395532942" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.025113883150590603" WEIGHT="16.59119211631994"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.336998939620113" CI_END="3.5607295647914827" CI_START="1.6513323172675762" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4248603678130185" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="36" I2="61.304049430936665" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.5515389905294265" LOG_CI_START="0.2178344803085849" LOG_EFFECT_SIZE="0.38468673541900567" METHOD="MH" MODIFIED="2013-10-30 14:25:13 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.035117947912621905" P_Q="1.0" P_Z="6.219079604439729E-6" Q="0.0" RANDOM="NO" SCALE="909.59" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2689" TOTAL_2="2715" WEIGHT="100.0" Z="4.51880105697445">
<NAME>Any symptomatic intracranial haemorrhage at end of treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11053" O_E="0.0" SE="0.0" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.541372732716139" CI_START="0.6663377773171338" EFFECT_SIZE="1.9215686274509804" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7436173633556353" LOG_CI_START="-0.1763055641665184" LOG_EFFECT_SIZE="0.2836558995945585" MODIFIED="2009-12-09 03:07:31 +0000" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.5403672813184454" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="0.29199679871948786" WEIGHT="14.258311762655135"/>
<DICH_DATA CI_END="10.156230667999193" CI_START="2.463717174828374" EFFECT_SIZE="5.002207505518764" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="9" LOG_CI_END="1.0067325559966407" LOG_CI_START="0.3915908510324525" LOG_EFFECT_SIZE="0.6991617035145465" MODIFIED="2008-08-30 07:32:41 +0100" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.3613372824965128" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.1305646317219647" WEIGHT="24.8734580860028"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11054" O_E="0.0" SE="0.0" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11055" O_E="0.0" SE="0.0" STUDY_ID="STD-Olinger-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0531057996744617" CI_START="0.2868846640662063" EFFECT_SIZE="0.76746632996633" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3124113298045396" LOG_CI_START="-0.5422926671232512" LOG_EFFECT_SIZE="-0.1149406686593558" MODIFIED="2011-12-05 14:22:57 +0000" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.5020573586484035" STUDY_ID="STD-RDTCI-2000" TOTAL_1="1056" TOTAL_2="1042" VAR="0.25206159137301165" WEIGHT="25.32963139353528"/>
<DICH_DATA CI_END="3.8674086497422504" CI_START="0.6587270318408747" EFFECT_SIZE="1.5961098398169336" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5874200642249526" LOG_CI_START="-0.181294514274526" LOG_EFFECT_SIZE="0.2030627749752133" MODIFIED="2011-12-05 14:22:57 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.45154674860912675" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="437" TOTAL_2="465" VAR="0.20389446617947393" WEIGHT="21.671691631773555"/>
<DICH_DATA CI_END="7.300223023099531" CI_START="0.9561109405631597" EFFECT_SIZE="2.641935483870968" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8633361280960639" LOG_CI_START="-0.019491712243772216" LOG_EFFECT_SIZE="0.4219222079261458" ORDER="11056" O_E="0.0" SE="0.518577443483909" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.26892256489030686" WEIGHT="13.86690712603323"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.3391808469867765" CI_START="0.01038780309060373" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.21230769230769234" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.6374077508924529" LOG_CI_START="-1.9834762913756911" LOG_EFFECT_SIZE="-0.673034270241619" METHOD="MH" MODIFIED="2013-10-30 14:22:48 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.3141153118601765" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="93" WEIGHT="100.0" Z="1.00662441280171">
<NAME>Any symptomatic intracranial haemorrhage at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.3391808469867765" CI_START="0.01038780309060373" EFFECT_SIZE="0.2123076923076923" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6374077508924529" LOG_CI_START="-1.9834762913756911" LOG_EFFECT_SIZE="-0.6730342702416191" ORDER="11057" O_E="0.0" SE="1.5395202600135525" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="2.370122630992196" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11058" O_E="0.0" SE="0.0" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11059" O_E="0.0" SE="0.0" STUDY_ID="STD-Olinger-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.274940976186041" CI_END="2.5552576205110378" CI_START="1.5377382697330824" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9822505977012383" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="80" I2="69.86803928412478" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.4074346921522036" LOG_CI_START="0.1868824227973141" LOG_EFFECT_SIZE="0.2971585574747589" METHOD="MH" MODIFIED="2013-10-30 14:22:57 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.01000767462988561" P_Q="1.0" P_Z="1.2815163837826377E-7" Q="0.0" RANDOM="NO" SCALE="740.42" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1186" TOTAL_2="1198" WEIGHT="100.0" Z="5.281469758184477">
<NAME>Any intracranial haemorrhage detected on systematic repeat CT during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5653466799723925" CI_START="0.32330932761610504" EFFECT_SIZE="0.9107142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.4091460638046174" LOG_CI_START="-0.4903817656211455" LOG_EFFECT_SIZE="-0.04061785090826406" ORDER="11060" O_E="0.0" SE="0.5283870997392616" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.27919292717086835" WEIGHT="8.476698170877626"/>
<DICH_DATA CI_END="1.7819193096361274" CI_START="0.45530909603021175" EFFECT_SIZE="0.9007352941176471" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.2508880340593338" LOG_CI_START="-0.3416936733986663" LOG_EFFECT_SIZE="-0.045402819669666236" MODIFIED="2009-12-09 03:08:16 +0000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.3480854282875893" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="0.12116346538615447" WEIGHT="20.38040431655292"/>
<DICH_DATA CI_END="5.0561217501905364" CI_START="2.076300702818916" EFFECT_SIZE="3.2400662251655628" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="24" LOG_CI_END="0.703817523106469" LOG_CI_START="0.3172902509672697" LOG_EFFECT_SIZE="0.5105538870368693" MODIFIED="2008-11-20 02:32:50 +0000" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.22704803299542067" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.05155080928708964" WEIGHT="29.627814111865707"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="11061" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="1.873198926153761"/>
<DICH_DATA CI_END="2.8184603126303847" CI_START="1.2879183774415495" EFFECT_SIZE="1.905241935483871" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="32" LOG_CI_END="0.4500119238015939" LOG_CI_START="0.10988834023653715" LOG_EFFECT_SIZE="0.2799501320190655" ORDER="11062" O_E="0.0" SE="0.19979027662500637" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.03991615463389657" WEIGHT="39.64188447454999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-10-30 14:23:07 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Recurrent stroke (ischaemic/unknown type) at end of treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11063" O_E="0.0" SE="0.0" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4332730781172924" CI_END="0.9189500204552303" CI_START="0.4941816755829873" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.673890392338091" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.036708108233862384" LOG_CI_START="-0.30611336241580317" LOG_EFFECT_SIZE="-0.17141073532483275" METHOD="MH" MODIFIED="2013-10-30 14:23:16 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.8052227023642067" P_Q="1.0" P_Z="0.012628476639603894" Q="0.0" RANDOM="NO" SCALE="352.87" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1331" TOTAL_2="1343" WEIGHT="100.0" Z="2.4940780670395735">
<NAME>Recurrent stroke (ischaemic/unknown type) at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11064" O_E="0.0" SE="0.0" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="11065" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Olinger-1988" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="1.6043765038948954"/>
<DICH_DATA CI_END="1.0826567964667042" CI_START="0.48319980117512246" EFFECT_SIZE="0.7232838646020016" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="53" LOG_CI_END="0.034490806557986496" LOG_CI_START="-0.3158732530884249" LOG_EFFECT_SIZE="-0.14069122326521918" MODIFIED="2008-11-29 16:15:06 +0000" MODIFIED_BY="[Empty name]" ORDER="11066" O_E="0.0" SE="0.2058055829663682" STUDY_ID="STD-RDTCI-2000" TOTAL_1="937" TOTAL_2="921" VAR="0.04235593798012666" WEIGHT="57.17613316105088"/>
<DICH_DATA CI_END="1.0127546652409405" CI_START="0.37788505659988647" EFFECT_SIZE="0.6186314363143631" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="40" LOG_CI_END="0.005504252432007595" LOG_CI_START="-0.4226402818446373" LOG_EFFECT_SIZE="-0.20856801470631484" MODIFIED="2008-11-29 16:15:33 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.2514942187837263" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="369" TOTAL_2="397" VAR="0.06324934208163678" WEIGHT="41.21949033505423"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4036246940390988" CI_END="0.8611517234963241" CI_START="0.23851643068974812" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4532094828781367" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="29" I2="0.0" I2_Q="25.863554140034424" ID="CMP-001.09" LOG_CI_END="-0.06492032488527626" LOG_CI_START="-0.6224816983341179" LOG_EFFECT_SIZE="-0.34370101160969707" METHOD="MH" MODIFIED="2013-10-30 14:24:58 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.49568619459396934" P_Q="0.24547693322488062" P_Z="0.01567545623080702" Q="1.3488642305417153" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="751" TOTAL_2="749" WEIGHT="200.0" Z="2.416385482509751">
<NAME>Venous thrombotic events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2795935797900309" CI_START="0.27920797879531295" DF="0" EFFECT_SIZE="0.5977229601518027" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.10707205239616047" LOG_CI_START="-0.5540721752420525" LOG_EFFECT_SIZE="-0.22350006142294607" NO="1" P_CHI2="1.0" P_Z="0.18512698841367164" STUDIES="1" TAU2="0.0" TOTAL_1="248" TOTAL_2="252" WEIGHT="100.0" Z="1.3251331634439443">
<NAME>Thrombophlebitis</NAME>
<DICH_DATA CI_END="1.2795935797900309" CI_START="0.27920797879531295" EFFECT_SIZE="0.5977229601518027" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.10707205239616047" LOG_CI_START="-0.5540721752420525" LOG_EFFECT_SIZE="-0.22350006142294607" ORDER="11067" O_E="0.0" SE="0.3883593920313948" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.15082301737899462" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06347515302459855" CI_END="0.8805487853325064" CI_START="0.07093110526491435" DF="1" EFFECT_SIZE="0.24991658324991656" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-0.05524657767083968" LOG_CI_START="-1.1491632728215169" LOG_EFFECT_SIZE="-0.6022049252461783" MODIFIED="2009-12-09 03:11:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8010853130169928" P_Z="0.03093297069027262" STUDIES="2" TAU2="0.0" TOTAL_1="503" TOTAL_2="497" WEIGHT="100.0" Z="2.1579339085460605">
<NAME>Pulmonary embolism/infarction</NAME>
<DICH_DATA CI_END="3.0579702853688486" CI_START="0.033541002377283184" EFFECT_SIZE="0.3202614379084967" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.485433261009905" LOG_CI_START="-1.4744239625880755" LOG_EFFECT_SIZE="-0.4944953507890852" MODIFIED="2009-12-09 03:11:17 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="1.1512298345911736" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="1.325330132052821" WEIGHT="25.525525525525524"/>
<DICH_DATA CI_END="1.034620621177585" CI_START="0.04928236741693415" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.014781130147282395" LOG_CI_START="-1.3073084377873143" LOG_EFFECT_SIZE="-0.6462636538200158" ORDER="11068" O_E="0.0" SE="0.7766019566536908" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.6031105990783411" WEIGHT="74.47447447447448"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-10-30 14:33:30 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Different agents</NAME>
<DICH_OUTCOME CHI2="5.980647904572219" CI_END="0.9910242361605143" CI_START="0.901413598932262" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.945157512453107" ESTIMABLE="YES" EVENTS_1="1451" EVENTS_2="1553" I2="16.397017851903833" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.0039157244228304735" LOG_CI_START="-0.045075894349474656" LOG_EFFECT_SIZE="-0.024495809386152582" METHOD="MH" MODIFIED="2013-10-30 14:33:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.30810679786335937" P_Q="0.6270220739049805" P_Z="0.0196543536354817" Q="0.2361207663581651" RANDOM="NO" SCALE="8.39" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2662" TOTAL_2="2692" WEIGHT="100.0" Z="2.3328817278734513">
<NAME>Death or dependency at the end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7229440483703957" CI_END="1.022887091323241" CI_START="0.895402852907075" DF="3" EFFECT_SIZE="0.9570245659191042" ESTIMABLE="YES" EVENTS_1="682" EVENTS_2="722" I2="19.418611694872023" ID="CMP-002.01.01" LOG_CI_END="0.009827697914008688" LOG_CI_START="-0.0479815262136568" LOG_EFFECT_SIZE="-0.01907691414982404" MODIFIED="2011-12-14 12:22:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29297739857897065" P_Z="0.19581487956375596" STUDIES="4" TAU2="0.0" TOTAL_1="1169" TOTAL_2="1185" WEIGHT="46.46610118584252" Z="1.2935674274833961">
<NAME>Ancrod versus control</NAME>
<DICH_DATA CI_END="1.0183366746189295" CI_START="0.55028101200679" EFFECT_SIZE="0.7485795454545454" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="0.007891384833885655" LOG_CI_START="-0.25941547269301696" LOG_EFFECT_SIZE="-0.12576204392956564" ORDER="11069" O_E="0.0" SE="0.15701737130158747" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.024654454890460583" WEIGHT="2.764688892364447"/>
<DICH_DATA CI_END="1.1133104537895433" CI_START="0.8451126889341236" EFFECT_SIZE="0.9699859747545582" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="155" LOG_CI_END="0.046616287036467224" LOG_CI_START="-0.07308537753642849" LOG_EFFECT_SIZE="-0.013234545249980623" MODIFIED="2009-12-18 08:11:13 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.07031335030291481" STUDY_ID="STD-ASP-2009" TOTAL_1="253" TOTAL_2="247" VAR="0.00494396723082041" WEIGHT="10.16411952319423"/>
<DICH_DATA CI_END="1.0971001087027665" CI_START="0.9071227236069508" EFFECT_SIZE="0.9975993377483444" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="360" LOG_CI_END="0.04024625808843265" LOG_CI_START="-0.042333953755990965" LOG_EFFECT_SIZE="-0.0010438478337791534" MODIFIED="2008-08-28 16:04:27 +0100" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.04850802521605576" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.0023530285103615014" WEIGHT="23.059813040445682"/>
<DICH_DATA CI_END="1.0452144319822532" CI_START="0.7925429826337423" EFFECT_SIZE="0.9101523847219474" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="163" LOG_CI_END="0.019205397694193393" LOG_CI_START="-0.10097717502257912" LOG_EFFECT_SIZE="-0.040885888664192876" ORDER="11070" O_E="0.0" SE="0.07059583812716176" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.004983772360876427" WEIGHT="10.477479729838162"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9912980926880537" CI_END="0.999761843059775" CI_START="0.8741661793333393" DF="1" EFFECT_SIZE="0.9348572033154695" ESTIMABLE="YES" EVENTS_1="769" EVENTS_2="831" I2="49.781501640967285" ID="CMP-002.01.02" LOG_CI_END="-1.0344256323784002E-4" LOG_CI_START="-0.05840599996606002" LOG_EFFECT_SIZE="-0.029254721264648925" MODIFIED="2011-12-14 12:22:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.15820556376736372" P_Z="0.049192565129179654" STUDIES="2" TAU2="0.0" TOTAL_1="1493" TOTAL_2="1507" WEIGHT="53.533898814157475" Z="1.9669188663650101">
<NAME>defibrase versus control</NAME>
<DICH_DATA CI_END="1.0474505592190828" CI_START="0.8898612284001511" EFFECT_SIZE="0.9654458251580553" ESTIMABLE="YES" EVENTS_1="544" EVENTS_2="556" LOG_CI_END="0.020133532960459288" LOG_CI_START="-0.050677715196790055" LOG_EFFECT_SIZE="-0.015272091118165373" MODIFIED="2009-12-18 08:13:31 +0000" MODIFIED_BY="[Empty name]" ORDER="11071" O_E="0.0" SE="0.041594877688899794" STUDY_ID="STD-RDTCI-2000" TOTAL_1="1056" TOTAL_2="1042" VAR="0.001730133849954534" WEIGHT="36.26776343930139"/>
<DICH_DATA CI_END="0.9799187616985338" CI_START="0.7734862674089638" EFFECT_SIZE="0.8706053671728728" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="275" LOG_CI_END="-0.008809927173292919" LOG_CI_START="-0.11154739242544331" LOG_EFFECT_SIZE="-0.06017865979936811" MODIFIED="2009-12-18 08:12:23 +0000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.06034849564776804" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="437" TOTAL_2="465" VAR="0.003641940926948678" WEIGHT="17.266135374856084"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.038250688276275" CI_END="1.2225148745514092" CI_START="0.9382156135552204" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0709727088528604" ESTIMABLE="YES" EVENTS_1="369" EVENTS_2="349" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.08725415196440882" LOG_CI_START="-0.02769734390596561" LOG_EFFECT_SIZE="0.02977840402922162" METHOD="MH" MODIFIED="2013-10-30 14:33:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5389167084378343" P_Q="0.48905173857663065" P_Z="0.3098843271253855" Q="0.4786119966136121" RANDOM="NO" SCALE="58.85" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2502" TOTAL_2="2526" WEIGHT="100.0" Z="1.0154648092648038">
<NAME>Death from all causes at the end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.494008330786468" CI_END="1.2868061475282562" CI_START="0.947891476618224" DF="4" EFFECT_SIZE="1.1044240939521226" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="245" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.10951312701328751" LOG_CI_START="-0.02324138186421459" LOG_EFFECT_SIZE="0.043135872574536445" MODIFIED="2011-12-14 12:23:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4787900207383282" P_Z="0.20276952711583696" STUDIES="6" TAU2="0.0" TOTAL_1="1196" TOTAL_2="1208" WEIGHT="70.1558452651599" Z="1.2737007187577085">
<NAME>Ancrod versus control</NAME>
<DICH_DATA CI_END="1.3495805044228693" CI_START="0.27313854028828644" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.1301987959572369" LOG_CI_START="-0.5636170158851276" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="11072" O_E="0.0" SE="0.4075508423198635" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.16609768907563024" WEIGHT="3.9147316821464786"/>
<DICH_DATA CI_END="1.6859512637023153" CI_START="0.7204074106356355" EFFECT_SIZE="1.102076124567474" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="34" LOG_CI_END="0.22684501618962832" LOG_CI_START="-0.14242182835998562" LOG_EFFECT_SIZE="0.042211593914821335" MODIFIED="2009-12-18 08:16:12 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.21690917238880375" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="0.04704958906639579" WEIGHT="10.000391799811865"/>
<DICH_DATA CI_END="1.448305956053406" CI_START="0.9604042196684184" EFFECT_SIZE="1.1793893129770991" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="131" LOG_CI_END="0.16086031668828346" LOG_CI_START="-0.017545940478105128" LOG_EFFECT_SIZE="0.07165718810508916" MODIFIED="2008-08-30 07:42:56 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.10479671858475248" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.010982352226131807" WEIGHT="37.342634211331"/>
<DICH_DATA CI_END="1.6359269307575819" CI_START="0.34384176299335795" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.21376390185519178" LOG_CI_START="-0.4636413750717917" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="11073" O_E="0.0" SE="0.39791121287711073" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.15833333333333333" WEIGHT="2.3068954555506034"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11074" O_E="0.0" SE="0.0" STUDY_ID="STD-Olinger-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5057552708909716" CI_START="0.8090371039065934" EFFECT_SIZE="1.103726362625139" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="58" LOG_CI_END="0.1777543920915685" LOG_CI_START="-0.09203156039962408" LOG_EFFECT_SIZE="0.042861415845972244" MODIFIED="2008-11-19 02:31:39 +0000" MODIFIED_BY="[Empty name]" ORDER="11075" O_E="0.0" SE="0.15847360395532942" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.025113883150590603" WEIGHT="16.59119211631994"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0783587245278292" CI_END="1.2893635239821777" CI_START="0.763735832939015" DF="1" EFFECT_SIZE="0.9923372032478235" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="104" I2="7.266480322875805" ID="CMP-002.02.02" LOG_CI_END="0.11037537988366837" LOG_CI_START="-0.11705683270156653" LOG_EFFECT_SIZE="-0.003340726408949083" MODIFIED="2011-12-14 12:24:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2990654422562583" P_Z="0.9540836709580343" STUDIES="2" TAU2="0.0" TOTAL_1="1306" TOTAL_2="1318" WEIGHT="29.844154734840103" Z="0.057579384813733425">
<NAME>Defibrase versus control</NAME>
<DICH_DATA CI_END="1.2409711667682781" CI_START="0.6558163998003659" EFFECT_SIZE="0.9021359336851801" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="73" LOG_CI_END="0.09376169104030672" LOG_CI_START="-0.18321772726142432" LOG_EFFECT_SIZE="-0.044728018110558786" MODIFIED="2008-11-29 16:26:39 +0000" MODIFIED_BY="[Empty name]" ORDER="11076" O_E="0.0" SE="0.1626990813806697" STUDY_ID="STD-RDTCI-2000" TOTAL_1="937" TOTAL_2="921" VAR="0.026470991082113787" WEIGHT="21.23169484057008"/>
<DICH_DATA CI_END="1.9283323694921612" CI_START="0.7651720374795907" EFFECT_SIZE="1.2147040825246962" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="31" LOG_CI_END="0.2851818914941178" LOG_CI_START="-0.1162409092540025" LOG_EFFECT_SIZE="0.08447049112005764" MODIFIED="2008-11-29 16:27:00 +0000" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.2357977402343567" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="369" TOTAL_2="397" VAR="0.05560057429962916" WEIGHT="8.612459894270023"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.336998939620115" CI_END="3.5607295647914827" CI_START="1.6513323172675762" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4248603678130185" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="36" I2="61.304049430936665" I2_Q="86.30633868234465" ID="CMP-002.03" LOG_CI_END="0.5515389905294265" LOG_CI_START="0.2178344803085849" LOG_EFFECT_SIZE="0.38468673541900567" METHOD="MH" MODIFIED="2013-10-30 14:33:19 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.035117947912622016" P_Q="0.0068853323987365656" P_Z="6.219079604439729E-6" Q="7.302648844620482" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2689" TOTAL_2="2715" WEIGHT="100.0" Z="4.51880105697445">
<NAME>Any symptomatic intracranial haemorrhage at the end of treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5174975070816545" CI_END="5.8733321403591" CI_START="2.1528080444586326" DF="2" EFFECT_SIZE="3.55586229760694" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="19" I2="20.556028580999488" ID="CMP-002.03.01" LOG_CI_END="0.7688845611437368" LOG_CI_START="0.3330053075991887" LOG_EFFECT_SIZE="0.5509449343714627" MODIFIED="2011-12-14 12:24:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2840092695491111" P_Z="7.243041551035123E-7" STUDIES="6" TAU2="0.0" TOTAL_1="1196" TOTAL_2="1208" WEIGHT="52.998676974691165" Z="4.954731018059288">
<NAME>Ancrod versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-01 03:34:04 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.541372732716139" CI_START="0.6663377773171338" EFFECT_SIZE="1.9215686274509804" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7436173633556353" LOG_CI_START="-0.1763055641665184" LOG_EFFECT_SIZE="0.2836558995945585" MODIFIED="2011-10-01 03:34:22 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.5403672813184454" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="0.29199679871948786" WEIGHT="14.258311762655135"/>
<DICH_DATA CI_END="10.156230667999193" CI_START="2.463717174828374" EFFECT_SIZE="5.002207505518764" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="9" LOG_CI_END="1.0067325559966407" LOG_CI_START="0.3915908510324525" LOG_EFFECT_SIZE="0.6991617035145465" MODIFIED="2011-10-01 03:34:35 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.3613372824965128" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.1305646317219647" WEIGHT="24.8734580860028"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-01 03:34:44 +0100" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.0" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-01 03:34:52 +0100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.0" STUDY_ID="STD-Olinger-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.300223023099531" CI_START="0.9561109405631597" EFFECT_SIZE="2.641935483870968" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8633361280960639" LOG_CI_START="-0.019491712243772216" LOG_EFFECT_SIZE="0.4219222079261458" MODIFIED="2011-10-01 03:35:06 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.518577443483909" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.26892256489030686" WEIGHT="13.86690712603323"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.175909657469036" CI_END="2.1959901056021063" CI_START="0.601755440301124" DF="1" EFFECT_SIZE="1.1495429495645246" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="14.959453419887236" ID="CMP-002.03.02" LOG_CI_END="0.34163037899659365" LOG_CI_START="-0.22057997470132823" LOG_EFFECT_SIZE="0.06052520214763269" MODIFIED="2011-12-14 12:24:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.27819033818290306" P_Z="0.6730228589219978" STUDIES="2" TAU2="0.0" TOTAL_1="1493" TOTAL_2="1507" WEIGHT="47.001323025308835" Z="0.4220029588074976">
<NAME>Defibrase versus control</NAME>
<DICH_DATA CI_END="2.0531057996744617" CI_START="0.2868846640662063" EFFECT_SIZE="0.76746632996633" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3124113298045396" LOG_CI_START="-0.5422926671232512" LOG_EFFECT_SIZE="-0.1149406686593558" MODIFIED="2011-10-01 03:35:35 +0100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.5020573586484035" STUDY_ID="STD-RDTCI-2000" TOTAL_1="1056" TOTAL_2="1042" VAR="0.25206159137301165" WEIGHT="25.32963139353528"/>
<DICH_DATA CI_END="3.8674086497422504" CI_START="0.6587270318408747" EFFECT_SIZE="1.5961098398169336" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5874200642249526" LOG_CI_START="-0.181294514274526" LOG_EFFECT_SIZE="0.2030627749752133" MODIFIED="2011-10-01 03:35:17 +0100" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.45154674860912675" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="437" TOTAL_2="465" VAR="0.20389446617947393" WEIGHT="21.671691631773555"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.43327307811729243" CI_END="0.9189500204552301" CI_START="0.49418167558298726" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6738903923380909" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.03670810823386249" LOG_CI_START="-0.3061133624158032" LOG_EFFECT_SIZE="-0.17141073532483284" METHOD="MH" MODIFIED="2013-10-30 14:33:30 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8052227023642067" P_Q="0.6530876699814301" P_Z="0.012628476639603864" Q="0.20202949478136722" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1331" TOTAL_2="1343" WEIGHT="100.00000000000001" Z="2.4940780670395744">
<NAME>Recurrent stroke (ischaemic/unknown type) at the end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.3225436971144395" CI_START="0.015173840636129785" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-12-14 12:22:54 +0000" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.48584124712227683" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="1.6043765038948954" Z="0.6969385642065118">
<NAME>Ancrod versus control</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11077" O_E="0.0" SE="0.0" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="11078" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Olinger-1988" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="1.6043765038948954"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23130775110098417" CI_END="0.928170412777976" CI_START="0.49736900748148677" DF="1" EFFECT_SIZE="0.6794432993098569" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="93" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-0.03237227967055497" LOG_CI_START="-0.30332128038317996" LOG_EFFECT_SIZE="-0.16784678002686745" MODIFIED="2011-12-14 12:22:58 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6305558638458808" P_Z="0.015169506938950746" STUDIES="2" TAU2="0.0" TOTAL_1="1306" TOTAL_2="1318" WEIGHT="98.39562349610512" Z="2.4283067507792326">
<NAME>Defibrase versus control</NAME>
<DICH_DATA CI_END="1.0826567964667042" CI_START="0.48319980117512246" EFFECT_SIZE="0.7232838646020016" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="53" LOG_CI_END="0.034490806557986496" LOG_CI_START="-0.3158732530884249" LOG_EFFECT_SIZE="-0.14069122326521918" MODIFIED="2008-11-29 16:28:37 +0000" MODIFIED_BY="[Empty name]" ORDER="11079" O_E="0.0" SE="0.2058055829663682" STUDY_ID="STD-RDTCI-2000" TOTAL_1="937" TOTAL_2="921" VAR="0.04235593798012666" WEIGHT="57.17613316105088"/>
<DICH_DATA CI_END="1.0127546652409405" CI_START="0.37788505659988647" EFFECT_SIZE="0.6186314363143631" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="40" LOG_CI_END="0.005504252432007595" LOG_CI_START="-0.4226402818446373" LOG_EFFECT_SIZE="-0.20856801470631484" MODIFIED="2008-11-29 16:28:20 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.2514942187837263" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="369" TOTAL_2="397" VAR="0.06324934208163678" WEIGHT="41.21949033505423"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-10-30 14:34:09 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Different treatment time from onset</NAME>
<DICH_OUTCOME CHI2="12.327982819081607" CI_END="0.9788833454909341" CI_START="0.913601922598892" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9456794945649148" ESTIMABLE="YES" EVENTS_1="2787" EVENTS_2="2985" I2="10.772101474915397" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.00926906042178718" LOG_CI_START="-0.039242995160824454" LOG_EFFECT_SIZE="-0.024256027791305822" METHOD="MH" MODIFIED="2013-10-30 14:33:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.33950157296381556" P_Q="0.890705772767903" P_Z="0.0015131370502307836" Q="0.6249147673984426" RANDOM="NO" SCALE="5.19" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5326" TOTAL_2="5382" WEIGHT="100.00000000000001" Z="3.172152157724287">
<NAME>Death or dependency at the end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.1222131693230235" CI_END="1.038019692746308" CI_START="0.891663801284875" DF="3" EFFECT_SIZE="0.9620626720971617" ESTIMABLE="YES" EVENTS_1="567" EVENTS_2="601" I2="27.223559850674114" ID="CMP-003.01.01" LOG_CI_END="0.01620559278982662" LOG_CI_START="-0.04979886397531256" LOG_EFFECT_SIZE="-0.01679663559274298" MODIFIED="2009-12-18 08:21:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24856624162786722" P_Z="0.31850603999134675" STUDIES="4" TAU2="0.0" TOTAL_1="1171" TOTAL_2="1183" WEIGHT="20.06900375471529" Z="0.9975326648126355">
<NAME>Treatment started &lt; 6 hours</NAME>
<DICH_DATA CI_END="1.0183366746189295" CI_START="0.55028101200679" EFFECT_SIZE="0.7485795454545454" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="0.007891384833885655" LOG_CI_START="-0.25941547269301696" LOG_EFFECT_SIZE="-0.12576204392956564" ORDER="11080" O_E="0.0" SE="0.15701737130158747" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.024654454890460583" WEIGHT="1.4393195195443433"/>
<DICH_DATA CI_END="1.6859512637023153" CI_START="0.7204074106356355" EFFECT_SIZE="1.102076124567474" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="34" LOG_CI_END="0.22684501618962832" LOG_CI_START="-0.14242182835998562" LOG_EFFECT_SIZE="0.042211593914821335" MODIFIED="2009-12-18 08:21:38 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.21690917238880375" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="0.04704958906639579" WEIGHT="1.1698968969796366"/>
<DICH_DATA CI_END="1.0971001087027665" CI_START="0.9071227236069508" EFFECT_SIZE="0.9975993377483444" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="360" LOG_CI_END="0.04024625808843265" LOG_CI_START="-0.042333953755990965" LOG_EFFECT_SIZE="-0.0010438478337791534" MODIFIED="2008-08-30 07:46:57 +0100" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.04850802521605576" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.0023530285103615014" WEIGHT="12.005126188998135"/>
<DICH_DATA CI_END="1.0452144319822532" CI_START="0.7925429826337423" EFFECT_SIZE="0.9101523847219474" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="163" LOG_CI_END="0.019205397694193393" LOG_CI_START="-0.10097717502257912" LOG_EFFECT_SIZE="-0.040885888664192876" ORDER="11081" O_E="0.0" SE="0.07059583812716176" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.004983772360876427" WEIGHT="5.454661149193176"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9912980926880537" CI_END="0.999761843059775" CI_START="0.8741661793333393" DF="1" EFFECT_SIZE="0.9348572033154695" ESTIMABLE="YES" EVENTS_1="769" EVENTS_2="831" I2="49.781501640967285" ID="CMP-003.01.02" LOG_CI_END="-1.0344256323784002E-4" LOG_CI_START="-0.05840599996606002" LOG_EFFECT_SIZE="-0.029254721264648925" MODIFIED="2009-12-18 08:22:37 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.15820556376736372" P_Z="0.049192565129179654" STUDIES="2" TAU2="0.0" TOTAL_1="1493" TOTAL_2="1507" WEIGHT="27.870183055074623" Z="1.9669188663650101">
<NAME>Treatment started &gt; 6 hours</NAME>
<DICH_DATA CI_END="1.0474505592190828" CI_START="0.8898612284001511" EFFECT_SIZE="0.9654458251580553" ESTIMABLE="YES" EVENTS_1="544" EVENTS_2="556" LOG_CI_END="0.020133532960459288" LOG_CI_START="-0.050677715196790055" LOG_EFFECT_SIZE="-0.015272091118165373" MODIFIED="2009-12-18 08:22:37 +0000" MODIFIED_BY="[Empty name]" ORDER="11082" O_E="0.0" SE="0.041594877688899794" STUDY_ID="STD-RDTCI-2000" TOTAL_1="1056" TOTAL_2="1042" VAR="0.001730133849954534" WEIGHT="18.881292572402014"/>
<DICH_DATA CI_END="0.9799187616985338" CI_START="0.7734862674089638" EFFECT_SIZE="0.8706053671728728" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="275" LOG_CI_END="-0.008809927173292919" LOG_CI_START="-0.11154739242544331" LOG_EFFECT_SIZE="-0.06017865979936811" MODIFIED="2009-12-18 08:22:30 +0000" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.06034849564776804" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="437" TOTAL_2="465" VAR="0.003641940926948678" WEIGHT="8.988890482672609"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0452144319822532" CI_START="0.7925429826337423" DF="0" EFFECT_SIZE="0.9101523847219474" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="163" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.019205397694193393" LOG_CI_START="-0.10097717502257912" LOG_EFFECT_SIZE="-0.040885888664192876" NO="3" P_CHI2="1.0" P_Z="0.18235064561279324" STUDIES="1" TAU2="0.0" TOTAL_1="248" TOTAL_2="252" WEIGHT="5.454661149193176" Z="1.3335522355072529">
<NAME>Treatment started &lt; 3 hours</NAME>
<DICH_DATA CI_END="1.0452144319822532" CI_START="0.7925429826337423" EFFECT_SIZE="0.9101523847219474" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="163" LOG_CI_END="0.019205397694193393" LOG_CI_START="-0.10097717502257912" LOG_EFFECT_SIZE="-0.040885888664192876" ORDER="11083" O_E="0.0" SE="0.07059583812716176" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.004983772360876427" WEIGHT="5.454661149193176"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.650197013638226" CI_END="0.9983057618896539" CI_START="0.9026131961449763" DF="4" EFFECT_SIZE="0.9492544203053079" ESTIMABLE="YES" EVENTS_1="1305" EVENTS_2="1390" I2="29.206008386168563" ID="CMP-003.01.04" LOG_CI_END="-7.36422276000367E-4" LOG_CI_START="-0.04449832141297925" LOG_EFFECT_SIZE="-0.022617371844489795" MODIFIED="2009-12-18 08:23:11 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.22683916422786232" P_Z="0.042772136068094435" STUDIES="5" TAU2="0.0" TOTAL_1="2414" TOTAL_2="2440" WEIGHT="46.60615204101693" Z="2.025928267024954">
<NAME>Treatment started &gt; 3 hours</NAME>
<DICH_DATA CI_END="1.0183366746189295" CI_START="0.55028101200679" EFFECT_SIZE="0.7485795454545454" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="44" LOG_CI_END="0.007891384833885655" LOG_CI_START="-0.25941547269301696" LOG_EFFECT_SIZE="-0.12576204392956564" ORDER="11084" O_E="0.0" SE="0.15701737130158747" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.024654454890460583" WEIGHT="1.4393195195443433"/>
<DICH_DATA CI_END="1.1133104537895433" CI_START="0.8451126889341236" EFFECT_SIZE="0.9699859747545582" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="155" LOG_CI_END="0.046616287036467224" LOG_CI_START="-0.07308537753642849" LOG_EFFECT_SIZE="-0.013234545249980623" MODIFIED="2009-12-18 08:22:59 +0000" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.07031335030291481" STUDY_ID="STD-ASP-2009" TOTAL_1="253" TOTAL_2="247" VAR="0.00494396723082041" WEIGHT="5.291523277399822"/>
<DICH_DATA CI_END="1.0971001087027665" CI_START="0.9071227236069508" EFFECT_SIZE="0.9975993377483444" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="360" LOG_CI_END="0.04024625808843265" LOG_CI_START="-0.042333953755990965" LOG_EFFECT_SIZE="-0.0010438478337791534" MODIFIED="2008-08-30 07:48:00 +0100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.04850802521605576" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.0023530285103615014" WEIGHT="12.005126188998135"/>
<DICH_DATA CI_END="1.0474505592190828" CI_START="0.8898612284001511" EFFECT_SIZE="0.9654458251580553" ESTIMABLE="YES" EVENTS_1="544" EVENTS_2="556" LOG_CI_END="0.020133532960459288" LOG_CI_START="-0.050677715196790055" LOG_EFFECT_SIZE="-0.015272091118165373" MODIFIED="2009-12-18 08:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="11085" O_E="0.0" SE="0.041594877688899794" STUDY_ID="STD-RDTCI-2000" TOTAL_1="1056" TOTAL_2="1042" VAR="0.001730133849954534" WEIGHT="18.881292572402014"/>
<DICH_DATA CI_END="0.9799187616985338" CI_START="0.7734862674089638" EFFECT_SIZE="0.8706053671728728" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="275" LOG_CI_END="-0.008809927173292919" LOG_CI_START="-0.11154739242544331" LOG_EFFECT_SIZE="-0.06017865979936811" MODIFIED="2009-12-18 08:23:06 +0000" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.06034849564776804" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="437" TOTAL_2="465" VAR="0.003641940926948678" WEIGHT="8.988890482672609"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.07650137655255" CI_END="1.1760340472704165" CI_START="0.975297055191377" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0709727088528604" ESTIMABLE="YES" EVENTS_1="738" EVENTS_2="698" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.07041989514796125" LOG_CI_START="-0.01086308708951798" LOG_EFFECT_SIZE="0.02977840402922162" METHOD="MH" MODIFIED="2013-10-30 14:34:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6876669738512374" P_Q="0.8357057007283393" P_Z="0.15097841035892345" Q="0.8573519455985052" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4984" TOTAL_2="5032" WEIGHT="99.99999999999997" Z="1.4360841053748936">
<NAME>Death from all causes at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.516616747742913" CI_END="1.3045354889307894" CI_START="0.9555245622415214" DF="3" EFFECT_SIZE="1.1164746759282638" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="237" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.11545589825966902" LOG_CI_START="-0.019758144706455233" LOG_EFFECT_SIZE="0.047848876776606895" MODIFIED="2009-12-18 08:24:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.47229584748764997" P_Z="0.16539153993844713" STUDIES="4" TAU2="0.0" TOTAL_1="1171" TOTAL_2="1183" WEIGHT="33.92447490480464" Z="1.3871647223260697">
<NAME>Treatment started &lt; 6 hours</NAME>
<DICH_DATA CI_END="1.3495805044228693" CI_START="0.27313854028828644" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.1301987959572369" LOG_CI_START="-0.5636170158851276" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="11086" O_E="0.0" SE="0.4075508423198635" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.16609768907563024" WEIGHT="1.9573658410732389"/>
<DICH_DATA CI_END="1.6859512637023153" CI_START="0.7204074106356355" EFFECT_SIZE="1.102076124567474" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="34" LOG_CI_END="0.22684501618962832" LOG_CI_START="-0.14242182835998562" LOG_EFFECT_SIZE="0.042211593914821335" MODIFIED="2009-12-18 08:24:59 +0000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.21690917238880375" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="0.04704958906639579" WEIGHT="5.000195899905932"/>
<DICH_DATA CI_END="1.448305956053406" CI_START="0.9604042196684184" EFFECT_SIZE="1.1793893129770991" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="131" LOG_CI_END="0.16086031668828346" LOG_CI_START="-0.017545940478105128" LOG_EFFECT_SIZE="0.07165718810508916" MODIFIED="2008-08-30 07:54:45 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.10479671858475248" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.010982352226131807" WEIGHT="18.671317105665498"/>
<DICH_DATA CI_END="1.5057552708909716" CI_START="0.8090371039065934" EFFECT_SIZE="1.103726362625139" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="58" LOG_CI_END="0.1777543920915685" LOG_CI_START="-0.09203156039962408" LOG_EFFECT_SIZE="0.042861415845972244" MODIFIED="2008-08-30 07:54:16 +0100" MODIFIED_BY="[Empty name]" ORDER="11087" O_E="0.0" SE="0.15847360395532942" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.025113883150590603" WEIGHT="8.295596058159969"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5316473814427911" CI_END="1.251953136286668" CI_START="0.7592342482759894" DF="2" EFFECT_SIZE="0.9749490747240985" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="112" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.09758807245825915" LOG_CI_START="-0.11962420956153284" LOG_EFFECT_SIZE="-0.011018068551636812" MODIFIED="2008-11-29 16:41:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4649509231901803" P_Z="0.8423895442349563" STUDIES="3" TAU2="0.0" TOTAL_1="1321" TOTAL_2="1333" WEIGHT="16.07552509519535" Z="0.1988379049250433">
<NAME>Treatment started &gt; 6 hours</NAME>
<DICH_DATA CI_END="1.6359269307575819" CI_START="0.34384176299335795" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.21376390185519178" LOG_CI_START="-0.4636413750717917" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="11088" O_E="0.0" SE="0.39791121287711073" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.15833333333333333" WEIGHT="1.1534477277753015"/>
<DICH_DATA CI_END="1.2409711667682781" CI_START="0.6558163998003659" EFFECT_SIZE="0.9021359336851801" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="73" LOG_CI_END="0.09376169104030672" LOG_CI_START="-0.18321772726142432" LOG_EFFECT_SIZE="-0.044728018110558786" MODIFIED="2008-11-29 16:41:08 +0000" MODIFIED_BY="[Empty name]" ORDER="11089" O_E="0.0" SE="0.1626990813806697" STUDY_ID="STD-RDTCI-2000" TOTAL_1="937" TOTAL_2="921" VAR="0.026470991082113787" WEIGHT="10.615847420285037"/>
<DICH_DATA CI_END="1.9283323694921612" CI_START="0.7651720374795907" EFFECT_SIZE="1.2147040825246962" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="31" LOG_CI_END="0.2851818914941178" LOG_CI_START="-0.1162409092540025" LOG_EFFECT_SIZE="0.08447049112005764" MODIFIED="2008-11-29 16:40:24 +0000" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.2357977402343567" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="369" TOTAL_2="397" VAR="0.05560057429962916" WEIGHT="4.306229947135011"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5057552708909716" CI_START="0.8090371039065934" DF="0" EFFECT_SIZE="1.103726362625139" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="58" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.1777543920915685" LOG_CI_START="-0.09203156039962408" LOG_EFFECT_SIZE="0.042861415845972244" MODIFIED="2008-08-30 07:56:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5334379562046533" STUDIES="1" TAU2="0.0" TOTAL_1="248" TOTAL_2="252" WEIGHT="8.295596058159969" Z="0.6227665347938562">
<NAME>Treatment started &lt; 3 hours</NAME>
<DICH_DATA CI_END="1.5057552708909716" CI_START="0.8090371039065934" EFFECT_SIZE="1.103726362625139" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="58" LOG_CI_END="0.1777543920915685" LOG_CI_START="-0.09203156039962408" LOG_EFFECT_SIZE="0.042861415845972244" MODIFIED="2008-08-30 07:56:53 +0100" MODIFIED_BY="[Empty name]" ORDER="11090" O_E="0.0" SE="0.15847360395532942" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.025113883150590603" WEIGHT="8.295596058159969"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.0028022763933615" CI_END="1.2320203186565908" CI_START="0.9196843956935492" DF="5" EFFECT_SIZE="1.064457543655857" ESTIMABLE="YES" EVENTS_1="306" EVENTS_2="291" I2="0.05601413444989734" ID="CMP-003.02.04" LOG_CI_END="0.09061787033463313" LOG_CI_START="-0.03636118213718206" LOG_EFFECT_SIZE="0.02712834409872554" MODIFIED="2009-12-18 08:26:08 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.41553846174128883" P_Z="0.4023284071693931" STUDIES="6" TAU2="0.0" TOTAL_1="2244" TOTAL_2="2264" WEIGHT="41.70440394184002" Z="0.8374700607490161">
<NAME>Treatment started &gt; 3 hours</NAME>
<DICH_DATA CI_END="1.3495805044228693" CI_START="0.27313854028828644" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.1301987959572369" LOG_CI_START="-0.5636170158851276" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="11091" O_E="0.0" SE="0.4075508423198635" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.16609768907563024" WEIGHT="1.9573658410732389"/>
<DICH_DATA CI_END="1.6859512637023153" CI_START="0.7204074106356355" EFFECT_SIZE="1.102076124567474" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="34" LOG_CI_END="0.22684501618962832" LOG_CI_START="-0.14242182835998562" LOG_EFFECT_SIZE="0.042211593914821335" MODIFIED="2009-12-18 08:26:08 +0000" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.21690917238880375" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="0.04704958906639579" WEIGHT="5.000195899905932"/>
<DICH_DATA CI_END="1.448305956053406" CI_START="0.9604042196684184" EFFECT_SIZE="1.1793893129770991" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="131" LOG_CI_END="0.16086031668828346" LOG_CI_START="-0.017545940478105128" LOG_EFFECT_SIZE="0.07165718810508916" MODIFIED="2008-08-30 07:57:12 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.10479671858475248" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.010982352226131807" WEIGHT="18.671317105665498"/>
<DICH_DATA CI_END="1.6359269307575819" CI_START="0.34384176299335795" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.21376390185519178" LOG_CI_START="-0.4636413750717917" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="11092" O_E="0.0" SE="0.39791121287711073" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.15833333333333333" WEIGHT="1.1534477277753015"/>
<DICH_DATA CI_END="1.2409711667682781" CI_START="0.6558163998003659" EFFECT_SIZE="0.9021359336851801" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="73" LOG_CI_END="0.09376169104030672" LOG_CI_START="-0.18321772726142432" LOG_EFFECT_SIZE="-0.044728018110558786" MODIFIED="2008-11-29 16:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="11093" O_E="0.0" SE="0.1626990813806697" STUDY_ID="STD-RDTCI-2000" TOTAL_1="937" TOTAL_2="921" VAR="0.026470991082113787" WEIGHT="10.615847420285037"/>
<DICH_DATA CI_END="1.9283323694921612" CI_START="0.7651720374795907" EFFECT_SIZE="1.2147040825246962" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="31" LOG_CI_END="0.2851818914941178" LOG_CI_START="-0.1162409092540025" LOG_EFFECT_SIZE="0.08447049112005764" MODIFIED="2008-11-29 16:41:17 +0000" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.2357977402343567" STUDY_ID="STD-RDTCI_x002d_2-2005" TOTAL_1="369" TOTAL_2="397" VAR="0.05560057429962916" WEIGHT="4.306229947135011"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="26.54988195237209" CI_END="2.372114018664501" CI_START="1.656462295307003" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9822505977012388" ESTIMABLE="YES" EVENTS_1="314" EVENTS_2="160" I2="66.10154419464038" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.3751355601082211" LOG_CI_START="0.21918155484129678" LOG_EFFECT_SIZE="0.29715855747475894" METHOD="MH" MODIFIED="2013-10-30 14:34:09 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0016596723894273246" P_Q="0.7228608017775262" P_Z="8.072911213650211E-14" Q="1.3264558698120994" RANDOM="NO" SCALE="607.16" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2372" TOTAL_2="2396" WEIGHT="100.0" Z="7.469126161287841">
<NAME>Any intracranial haemorrhage detected on systematic repeat CT during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Treatment worse</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.06218797611728" CI_END="2.6001653181616957" CI_START="1.5595544375445645" DF="3" EFFECT_SIZE="2.0137277274469225" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="79" I2="75.1288903311746" ID="CMP-003.03.01" LOG_CI_END="0.41500096123347957" LOG_CI_START="0.19300053876779377" LOG_EFFECT_SIZE="0.3040007500006367" MODIFIED="2009-12-18 08:27:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.007173151958593471" P_Z="7.968858735618963E-8" STUDIES="4" TAU2="0.0" TOTAL_1="1171" TOTAL_2="1183" WEIGHT="49.063400536923126" Z="5.367832319026412">
<NAME>Treatment started &lt; 6 hours</NAME>
<DICH_DATA CI_END="2.5653466799723925" CI_START="0.32330932761610504" EFFECT_SIZE="0.9107142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.4091460638046174" LOG_CI_START="-0.4903817656211455" LOG_EFFECT_SIZE="-0.04061785090826406" ORDER="11094" O_E="0.0" SE="0.5283870997392616" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.27919292717086835" WEIGHT="4.238349085438813"/>
<DICH_DATA CI_END="1.7819193096361274" CI_START="0.45530909603021175" EFFECT_SIZE="0.9007352941176471" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.2508880340593338" LOG_CI_START="-0.3416936733986663" LOG_EFFECT_SIZE="-0.045402819669666236" MODIFIED="2009-12-18 08:27:11 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.3480854282875893" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="0.12116346538615447" WEIGHT="10.19020215827646"/>
<DICH_DATA CI_END="5.0561217501905364" CI_START="2.076300702818916" EFFECT_SIZE="3.2400662251655628" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="24" LOG_CI_END="0.703817523106469" LOG_CI_START="0.3172902509672697" LOG_EFFECT_SIZE="0.5105538870368693" MODIFIED="2008-11-29 16:44:02 +0000" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.22704803299542067" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.05155080928708964" WEIGHT="14.813907055932853"/>
<DICH_DATA CI_END="2.8184603126303847" CI_START="1.2879183774415495" EFFECT_SIZE="1.905241935483871" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="32" LOG_CI_END="0.4500119238015939" LOG_CI_START="0.10988834023653715" LOG_EFFECT_SIZE="0.2799501320190655" MODIFIED="2008-11-19 02:39:16 +0000" MODIFIED_BY="[Empty name]" ORDER="11095" O_E="0.0" SE="0.19979027662500637" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.03991615463389657" WEIGHT="19.820942237274995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-11-29 16:43:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.9365994630768805" Z="0.6891046110061">
<NAME>Treatment started &gt; 6 hours</NAME>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="11096" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.9365994630768805"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8184603126303847" CI_START="1.2879183774415495" DF="0" EFFECT_SIZE="1.905241935483871" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="32" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.4500119238015939" LOG_CI_START="0.10988834023653715" LOG_EFFECT_SIZE="0.2799501320190655" MODIFIED="2008-11-19 02:40:43 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0012534563675015314" STUDIES="1" TAU2="0.0" TOTAL_1="248" TOTAL_2="252" WEIGHT="19.820942237274995" Z="3.2264282909958895">
<NAME>Treatment started &lt; 3 hours</NAME>
<DICH_DATA CI_END="2.8184603126303847" CI_START="1.2879183774415495" EFFECT_SIZE="1.905241935483871" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="32" LOG_CI_END="0.4500119238015939" LOG_CI_START="0.10988834023653715" LOG_EFFECT_SIZE="0.2799501320190655" MODIFIED="2008-11-19 02:40:43 +0000" MODIFIED_BY="[Empty name]" ORDER="11097" O_E="0.0" SE="0.19979027662500637" STUDY_ID="STD-STAT-2000" TOTAL_1="248" TOTAL_2="252" VAR="0.03991615463389657" WEIGHT="19.820942237274995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.279146787999862" CI_END="2.834798828976023" CI_START="1.4577367643147736" DF="3" EFFECT_SIZE="2.032828195503697" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="48" I2="77.40818707786973" ID="CMP-003.03.04" LOG_CI_END="0.45252224468727903" LOG_CI_START="0.16367910688529358" LOG_EFFECT_SIZE="0.3081006757862863" MODIFIED="2009-12-18 08:27:33 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.004070245676846551" P_Z="2.8987960677782003E-5" STUDIES="4" TAU2="0.0" TOTAL_1="938" TOTAL_2="946" WEIGHT="30.17905776272501" Z="4.181274533636661">
<NAME>Treatment started &gt; 3 hours</NAME>
<DICH_DATA CI_END="2.5653466799723925" CI_START="0.32330932761610504" EFFECT_SIZE="0.9107142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.4091460638046174" LOG_CI_START="-0.4903817656211455" LOG_EFFECT_SIZE="-0.04061785090826406" ORDER="11098" O_E="0.0" SE="0.5283870997392616" STUDY_ID="STD-AISS-1994" TOTAL_1="64" TOTAL_2="68" VAR="0.27919292717086835" WEIGHT="4.238349085438813"/>
<DICH_DATA CI_END="1.7819193096361274" CI_START="0.45530909603021175" EFFECT_SIZE="0.9007352941176471" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.2508880340593338" LOG_CI_START="-0.3416936733986663" LOG_EFFECT_SIZE="-0.045402819669666236" MODIFIED="2009-12-18 08:27:33 +0000" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.3480854282875893" STUDY_ID="STD-ASP-2009" TOTAL_1="255" TOTAL_2="245" VAR="0.12116346538615447" WEIGHT="10.19020215827646"/>
<DICH_DATA CI_END="5.0561217501905364" CI_START="2.076300702818916" EFFECT_SIZE="3.2400662251655628" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="24" LOG_CI_END="0.703817523106469" LOG_CI_START="0.3172902509672697" LOG_EFFECT_SIZE="0.5105538870368693" MODIFIED="2008-11-29 16:44:48 +0000" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.22704803299542067" STUDY_ID="STD-ESTAT-2006" TOTAL_1="604" TOTAL_2="618" VAR="0.05155080928708964" WEIGHT="14.813907055932853"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="11099" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Hossmann-1983" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="0.9365994630768805"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-07-07 14:16:04 +0100" MODIFIED_BY="[Empty name]"/>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-12-13 15:01:58 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-12-13 15:01:49 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-09-02 14:58:57 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-13 15:01:49 +0000" MODIFIED_BY="[Empty name]">
<P>We used the following search strategy for MEDLINE (Ovid) and adapted it for CENTRAL.</P>
<P>1. exp snakes/ or exp snake venoms/ or venoms/<BR/>2. ancrod/ or batroxobin/ or venombin a/<BR/>3. Fibrinogen/de, ai [Drug Effects, Antagonists &amp; Inhibitors]<BR/>4. (batroxobin or defibrase or defibrol or hemocoagulase or reptilase or ancrod or agkistrodon or arvin or arwin or venacil or viprinex or venom$ or defibrinogen$ or fibrinogen deplet$ or acutase or acutobin).tw.<BR/>5. 1 or 2 or 3 or 4<BR/>6. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain ischemia/ or carotid artery diseases/ or carotid artery thrombosis/ or intracranial arterial diseases/ or cerebral arterial diseases/ or exp "intracranial embolism and thrombosis"/ or exp stroke/<BR/>7. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.<BR/>8. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>9. 6 or 7 or 8<BR/>10. 9 and 5<BR/>11. limit 10 to humans</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-12-13 15:01:58 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-09-02 14:59:13 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-13 15:01:58 +0000" MODIFIED_BY="[Empty name]">
<P>We used the following search strategy for EMBASE (Ovid).</P>
<P>1. exp snake venom/ or exp snake/ or venom/<BR/>2. ancrod/ or batroxobin/ or venombin a/<BR/>3. fibrinogen/pd<BR/>4. (batroxobin or defibrase or defibrol or hemocoagulase or reptilase or ancrod or agkistrodon or arvin or arwin or venacil or viprinex or venom$ or defibrinogen$ or fibrinogen deplet$ or acutase or acutobin).tw.<BR/>5. 1 or 2 or 3 or 4<BR/>6. cerebrovascular disease/ or cerebral artery disease/ or cerebrovascular accident/ or stroke/ or vertebrobasilar insufficiency/ or carotid artery disease/ or exp carotid artery obstruction/ or exp brain infarction/ or exp brain ischemia/ or exp occlusive cerebrovascular disease/<BR/>7. stroke patient/ or stroke unit/<BR/>8. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.<BR/>9. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>10. 6 or 7 or 8 or 9<BR/>11. 10 and 5<BR/>12. limit 11 to human</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>